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% Percentage
± Positive or negative
β Beta
κ Kappa
µg/ml Microgram per milliliter
cfu Colony forming units
CHF Congestive heart failure
DM Diabetes mellitus
EDTA Ethylene diamine tetra acetic acid
g Gram
h Hour
mg/ml Milligram per milliliter
MIC Minimal inhibitory concentration
min Minute
mL Milliliter
mm Millimeter
nm Nanometer
nmol Nanomol
oC Degree Celsius
rpm Revolutions per minute
SDA Sabouraud dextrose agar
SRB Sulphorodamine B
temp Temperature
UV Ultraviolet
w/v Weight by volume
1. INTRODUCTION
1.1 ANTIFUNGAL DRUGS1-3
The  use  of  chemical  or  synthetic  agents  with  antimicrobial  activity  (as  inhibitors,  growth 
reducers or even inactivators) is one of the oldest techniques for controlling microorganism growth. In 
the  United  States,  only  10  antifungal  drugs  are  currently  approved  by  the  Food  and  Drug 
Administration (FDA) for the therapy of systemic fungal infections. As shown in table, these drugs 
belong to 3 principle classes: polyenes, pyrimidines, and azoles. Drugs that belong to other classes are 
also approved as topical antifungal drugs.1, 2
Although conventional  amphotericin  B (Fungizone)  remains  the  standard  therapy for  many 
invasive or life-threatening mycoses, this polyene drug is associated with significant toxicity, including 
infusion-related  events,  such  as  chills,  fever,  headache,  nausea  and  vomiting,  and  dose-limiting 
nephrotoxicity. In addition, the clinical efficacy of amphotericin B in some settings (e.g., mold disease 
such as invasive aspergillosis in severely immunocompromised patients) is suboptimal. Consequently, 
3 new lipid formulations of amphotericin B (amphotericin B lipid complex, amphotericin B cholesteryl 
sulfate, and liposomal amphotericin B) have been developed and recently approved by the FDA. These 
lipid  formulations  offer  several  advantages  over  conventional  amphotericin  B,  including  increased 
daily  dose  of  the  parent  drug  (up  to  10-fold),  high  tissue  concentrations  in  the  primary 
reticuloendothelial  organs  (lungs,  liver,  and  spleen),  decrease  in  infusion-associated  side  effects 
(especially liposomal amphotericin B), and marked decrease in nephrotoxicity.
Although the therapeutic : toxic ratio of these compounds is clearly improved, superiority in 
clinical efficacy has not been definitively established in head-to-head comparative trials, either a lipid 
formulation  versus  conventional  amphotericin  B  or  1  lipid  formulation  versus  another  lipid 
formulation.
Moreover, these lipid formulations of amphotericin B are considerably more expensive than 
conventional amphotericin B, ranging from 10- to 20-fold higher in cost per dose. In addition, the 
optimum  daily  or  total  dose  of  these  lipid  compounds  has  not  been  established.  Accordingly, 
unanswered questions and controversy abound about several issues relating to these 3 lipid agents.
 Diffusion assays3
Diffusion assays are carried out on a solid medium, usually an agar medium, which is suitable 
for growth of the test microorganisms. The compound to be assayed is allowed to diffuse through the 
medium in a radial fashion from a pad/cap so that the adjacent growth of the test microorganism is 
either depressed, as with an antibiotic or stimulated, as with a growth factor. The diameter of these 
areas reflects the concentration of the compound being assayed, and it is compared with similar zones 
produced by various known concentration of standard or reference compound. The zone diameter of 
the standard are plotted against logs of the concentration used and the linear portion of this standard 
curve is used for determining the actual concentration of the sample being assayed.3
There are two types of diffusion assay and although somewhat similar, each has its particular 
advantages. In the cylinder method, the portion of the antibiotic solution or other fermentation product 
diffuses from a reservoir or cylinder into the surrounding agar while in the paper disc method only a 
defined amount of fermentation solution, such as 0.1ml, is applied to the disc. A standardized amount 
of agar medium, perhaps 10ml is placed in petri pleats and allowed to harden. As soon as this base 
layer is hard a standardized amount (usually 5ml) of the same or a different agar medium inoculated 
with a test microorganism is added above the base layer and allowed to harden to form the “seeded 
agar” layer. Several small metals, glazed porcelain or glass cylinders are set on the agar surface. A 
slight preheating of these cylinders helps to seal them to the agar. The number of cylinders used per 
plate depends on the expected sizes of the zones, since the zones should not overlap. In fact, it is often 
necessary to dilute the samples to hold down the sizes of the zones.  The cylinders are filled with 
appropriate dilutions of the solutions to be assayed or with solution containing known concentration of 
the  reference  compound  and  the  plates  are  incubated  for  a  specified  period  of  time  at  constant 
temperature. The diameters of the zones of stimulated/reduced growth are then measured in mm and 
the concentration in the solutions under assay are determined by comparison with a standard, curve 
prepared from the inhibition/stimulation zone data for the standards. 
To  obtain  valid  and  reproducible  results,  each  sample  of  unknown  compound  and  each 
concentration of reference compound should be replicated several  times on different plates so that 
average values can be calculated. Each assay plate also should contain a cylinder with at least one 
concentration of standard solution in addition to the fermentation samples, because variability in zone 
sizes is likely to be greater when comparing values from different plates than when comparing values 
from the same plate.3
1.2 HEART FAILURE4-10
Congestive heart failure (CHF) is a major contributor to morbidity and mortality worldwide. 
There are approximately 5 million established cases of heart failure in the United States alone; a similar 
number of patients have asymptomatic left ventricular dysfunction and are therefore at risk to develop 
CHF. Heart failure accounts for more than half a million deaths annually in the United States; mortality 
in patients with advanced heart failure exceeds 50% at 1 year.
Heart  failure  develops  when  the  heart  can  no  longer  provide  adequate  blood  flow  and/or 
pressure to meet the body’s demands. This failure triggers countermeasures, including the retention of 
salt  and  water  by  the  kidneys,  the  stimulation  of  the  body’s  organs  by  neurohormones,  and  the 
activation of intracellular signaling cascades in the heart and vasculature that alter cellular and organ 
morphology  and  function.  Such  ‘compensatory’  responses  can  initially  offset  reduced  cardiac 
performance, but they become key ‘co-conspirators’ in the disease process, ultimately increasing the 
likelihood of organ failure and worsening clinical prognosis. Although individuals with heart failure 
have some symptoms in common, including fatigue, shortness of breath and fluid retention, the clinical 
presentation of heart dysfunction is heterogeneous. About half of all individuals have contractile failure 
and a dilated heart (that is, systolic heart failure), and the other half seem to have normal contraction 
and a non-dilated, but often hypertrophied, heart (that is, heart failure with a preserved ejection fraction 
(HFpEF),  which  has  also  been  termed  diastolic  heart  failure).  HFpEF is  increasing  in  prevalence 
worldwide but remains understudied.4
 Diagnosis
Diagnosis  is  the  first  essential  step  in  the  provision  of  good management  of  heart  failure. 
Diagnosis of heart failure by clinical means alone may be fairly accurate in advanced heart failure but 
will only be correct in about 50% of milder cases; little better than guessing. In at risk groups, such as 
those who have had a myocardial infarction, symptoms alert the clinician to a possible diagnosis of 
heart failure which must be confirmed by further investigation. The echocardiogram is the single most 
useful diagnostic tool for heart failure in widespread use at the present.5
 Therapy
In recent decades, therapy for heart failure has undergone several large shifts, moving from a 
focus on haemodynamics to a focus on the targeting of specific disease mechanisms. 
One  such  shift  is  that  neurohormonal  stimulation  is  no  longer  viewed  as  always  having 
beneficial  effects  but  as often worsening heart  failure  and it  is  therefore a  process  that  should be 
blocked. For example, arterial vasodilators have long been known to have therapeutic effects through 
reducing  the  workload  of  the  heart;  however,  more  recently,  inhibitors  of  the  renin–angiotensin–
aldosterone system were found to be more effective than arterial vasodilators, even though they have 
similar  effects  on  workload.  An  even  more  remarkable  example  is  the  use  of  β-blockers,  which 
antagonize  the  activation  of  β-adrenergic  receptors  (β-ARs)  on  cardiomyocyte  by the  sympathetic 
nervous system. Although β-blockers were long considered to be contra indicated for heart failure, they 
were ultimately shown to improve outcome and are now established therapeutics.
A second shift has been to avoid treatments designed to stimulate muscle in the weakened heart. 
Although such therapy helped in the short term, it was generally found to be detrimental when carried 
out long term.
A third shift is that a ‘bionic’ era is now dawning, in which implantable devices controlled by 
microprocessors can deliver therapy, monitor disease and rescue a patient from sudden cardiac death. 
Since the turn of the twenty-first century, these devices have had the most impact of any new treatment 
for heart failure.6
The ability to replace damaged myocardium by the use of stem cell therapy offers a new and 
potentially exciting treatment modality, but its benefits are at present far from established. The current 
state of cardiac stem cell therapy and its future has been reviewed briefly.7
The pharmacological treatment of heart failure for many years was limited to the use of digitalis 
glycosides and diuretics. Although digitalis has been supplanted by therapies that provide a mortality 
benefit  (e.g., ACE  inhibitors),  the  clinical  and  investigative  uses  of  the  cardiac  glycosides  have 
informed approaches to therapy and drug design and development. Similarly, while diuretics do not 
offer a mortality benefit, volume overload clearly remains a central component of the clinical syndrome 
and  is  often  the  factor  that  leads  to  initial  diagnosis  or  to  hospitalization  for  treatment  of  acute 
exacerbations.
The current approach to therapy for CHF involves preload reduction, afterload reduction, and 
enhancement of ionotropic state. A variety of vasodilators will reduce preload and afterload. Although 
a vasodilator's more prominent effect may be the reduction of either preload or afterload, most agents 
affect both, to differing extents.4
 Cardiac Glycosides
The beneficial effects of cardiac glycosides in the treatment of heart failure have been attributed 
to a positive ionotropic effect on failing myocardium and efficacy in controlling the ventricular rate 
response to atrial fibrillation. The cardiac glycosides also modulate autonomic nervous system activity, 
and it is likely that this mechanism contributes substantially to their efficacy in the management of 
heart  failure.  The  cardiac  glycosides  possess  a  common  molecular  structure,  a  steroid  nucleus 
containing an unsaturated lactone at  the C17 position,  and one or more glycosidic  residues at  C3. 
However, the advent of alternative therapies that both palliate symptoms and improve survival has led 
to a more limited role for the cardiac glycosides in the pharmacotherapy of congestive heart failure. 
Only digoxin (LANOXIN, LANOXICAPS) is in widespread clinical use today4.
• Mechanisms of Action: Inhibition of Na+, K+-ATPase
All cardiac glycosides are potent and highly selective inhibitors of the active transport of Na+ 
and K+ across cell membranes. This biological effect is accomplished by binding to a specific site on 
the  β subunit  of  Na+,  K+-ATPase,  the cellular  Na+ pump.  The Na+,  K+-ATPase is  a  heterodimeric 
(designated,  α-  and  β-  subunits)  transmembrane  protein  complex  that  serves  as  the  receptor  for 
cardiotonic steroids such as digitalis. Na+, K+-ATPase and other P2-type ATPases use the hydrolysis of 
ATP to drive ion transport across cell membranes. This enzyme also plays an important role in the 
regulation  of  blood  pressure,  and  it  specifically  mediates  adrenocorticotropic  hormone  (ACTH)-
induced hypertension in mice. The binding of cardiac glycosides to Na+, K+-ATPase and inhibition of 
the cellular ion pump is reversible and entropically driven.8-10
Figure 1.1: Mechanism of action of Cardiac Glycoside10
• Electrophysiological Actions
At therapeutic serum or plasma concentrations (i.e., 1 to 2 ng/ml), cardiac glycoside decreases 
automaticity  and  increases   maximal  diastolic  resting  membrane  potential  in  atrial  and  AV nodal 
tissues, due to an increase in vagal tone and a decrease in sympathetic nervous system activity.  In 
addition, there is prolongation of the effective refractory period and decreased conduction velocity in 
AV nodal tissue. These aggregate effects may cause sinus bradycardia or arrest and/or prolongation of 
AV conduction or higher-grade AV block. At higher concentrations, cardiac glycosides can increase 
sympathetic  nervous system activity and directly affect  automaticity in  cardiac  tissue,  actions  that 
contribute to the genesis of atrial and ventricular arrhythmias. Increased intracellular Ca2+ loading and 
increased sympathetic tone increase the spontaneous (phase 4) rate of diastolic depolarization as well as 
delayed  afterdepolarizations  that  may  reach  the  threshold  for  generation  of  a  propagated  action 
potential.4, 10
Figure 1.2: Action of Cardiac Glycoside on Heart10
Inhibition of Na+-K+ATPase
Incresed Na+ infflux Incresed K+ efflux
Increased sensitivity of Pacemaker
Increase in [Ca2+]i
Slows AV conduction
Increase in force of contraction
(Helps in CHF)
Prolongation of depolarization
(Helps in arrythmias)
This simultaneous nonuniform increase in automaticity and depression of conduction in HIS-
Purkinje and ventricular  muscle fibers produces an electrophysiologic substrate that  predisposes to 
serious ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation.10
• Clinical Use of Cardiac glycoside in Heart Failure
The cardiac glycosides have long been used in the treatment of CHF. For a century, however, 
there has been controversy surrounding the efficacy of cardiac glycosides in the treatment of patients 
with heart failure who are in sinus rhythm.
The PROVED (Prospective Randomized study Of Ventricular failure and Efficacy of Digoxin) 
and  RADIANCE  (Randomized  Assessment  of  Digoxin  on  Inhibition  of  Angiotensin  Converting 
Enzyme) trials examined the effects of withdrawal of cardiac glycoside in stable patients with mild-to-
moderate heart failure (i.e. NYHA Class II and III) and systolic ventricular dysfunction (left ventricular 
ejection fraction  <0.35%). All patients studied were in normal sinus rhythm. Withdrawal of cardiac 
glycoside  resulted  in  a  significant  worsening  of  heart  failure  symptoms  in  patients  who  received 
placebo compared with patients who continued to receive active drug.4
• Use of Cardiac glycoside in Clinical Practice and Monitoring of Serum Levels
It is now recommended that cardiac glycoside be reserved for patients with heart failure who 
are  in  atrial  fibrillation,  or for patients  in sinus rhythm who remain symptomatic despite  maximal 
therapy with ACE inhibitors and  β adrenergic receptor antagonists. The latter agents are viewed as 
first-line therapies on the basis of the proven mortality benefit. Most studies suggest that the maximal 
increase in contractility is apparent at serum levels of cardiac glycoside around 1.4ng/ml or 1.8 nmol. 
The neurohormonal benefits of cardiac glycoside may occur at lower serum levels, between 0.5 and 1 
ng/ml;  higher  serum  concentrations  are  not  associated  with  further  decreases  in  neurohormonal 
activation  or  with  increased  clinical  benefit.  A  retrospective  subgroup  analysis  of  the  DIG  trial 
suggested that the risk of death was greater with increasing serum concentrations, even at values that 
were within the traditional therapeutic range. Many authorities therefore advocate maintaining cardiac 
glycoside levels below 1 ng/ml.
In summary,  cardiac glycoside is  no longer viewed as a first-line agent in the treatment of 
congestive  heart  failure.  Despite  this  fact,  it  should  be  emphasized  that  cardiac  glycoside,  unlike 
virtually all other ionotropic agents studied to date, does not have an adverse impact on mortality in 
CHF. The ionotropic effects of digitalis were first identified more than 200 years ago and, despite the 
development  of  newer  pharmacological  agents  such  as  angiotensin-converting  enzyme  (ACE) 
inhibitors, angiotensin II receptor antagonists and b-blockers, the cardiac glycosides remains first-line 
agents  in  the  treatment  of  CHF  and  supraventricular  arrhythmias.  Thus,  cardiac  glycoside  is  a 
therapeutic option in patients  who remain symptomatic despite  treatment with agents that  improve 
survival.  Cardiac  glycoside  may be  unique  among ionotropic  drugs  by virtue  of  its  neurohumoral 
effects, which include attenuation of sympathetic activation and reduction of renin release.4
• Cardiac glycoside Toxicity
Vigilance for and early recognition of disturbances of impulse formation, conduction, or both 
are critically important. Among the more common electrophysiological manifestations are ectopic beats 
of AV junctional or ventricular origin,  first-degree AV block,  an excessively slow ventricular  rate 
response to atrial fibrillation, or an accelerated AV junctional pacemaker. These often require only a 
dosage adjustment and appropriate monitoring. Sinus bradycardia, sinoatrial arrest or exit block, and 
second-  or  third-degree  AV  conduction  delay  usually  respond  to  atropine,  although  temporary 
ventricular pacing may be necessary. Potassium administration should be considered for patients with 
evidence of increased AV junctional or ventricular automaticity, even when the serum K+ is in the 
normal range, unless high-grade AV block also is present. Lidocaine or phenytoin, which has minimal 
effects on AV conduction, may be used for the treatment of worsening ventricular arrhythmias that 
threaten  hemodynamic  compromise.  Electrical  cardioversion  carries  an  increased  risk  of  inducing 
severe rhythm disturbances in patients with overt digitalis toxicity and should be used with particular 
caution.  Note,  too,  that  inhibition  of  the  Na+,  K+-ATPase  activity  of  skeletal  muscle  can  cause 
hyperkalemia.4
• Anticardiac glycoside Immunotherapy
An effective antidote for life-threatening cardiac glycoside or digitoxin toxicity is available in 
the form of anticardiac glycoside immunotherapy with purified Fab fragments from ovine anticardiac 
glycoside antisera (DIGIBIND). A full neutralizing dose of Fab based on either the estimated total dose 
of drug ingested or the total body cardiac glycoside burden can be administered intravenously in saline 
solution over 30 to 60 minutes.4
1.3 DIABETES11-14
Diabetes  mellitus  (DM)  is  a  group  of  syndrome  characterized  by  hyperglycemia;  altered 
metabolism of lipids, carbohydrates and proteins; and an increased risk of complications from vascular 
disease.  Most patients  can be classified clinically as having either type 1 DM (formerly known as 
insulin-dependent diabetes mellitus or IDDM) or type 2 DM (formerly known as non-insulin-dependent 
diabetes mellitus or NIDDM).
The incidence of each type of diabetes varies widely throughout the world. In the United States, 
about  5% to  10% of  all  diabetic  patients  have  type  1  DM, with  an  incidence  of  18  per  100,000 
inhabitants per year, the remaining 90% having type 2 DM. The incident rates of type 2 DM increase 
with age, with a mean rate of about 440 per 100,000 per year by the sixth decade in males in the United 
States.
There are more than 125 million persons with diabetes in the world today, and by 2010 this 
number is expected to approach 220 million. Both type 1 and type 2 DM are increasing in frequency. 
The reason for the increase of type 1 DM is not known. The genetic basis for type 2 DM cannot change 
in  such  a  short  time;  thus  other  contributing  factors,  including  increasing  age,  obesity,  sedentary 
lifestyle, and low birth weight, must account for this dramatic increase. In addition, type 2 DM is being 
diagnosed  with  remarkable  frequency  in  preadolescents  and  adolescents.  Up  to  45%  of  newly 
diagnosed children and adolescents have type 2 DM.  Direct costs for medical services and indirect 
costs because of lost productivity due to diabetes approached 132 billion dollars in 200211.
Undiagnosed diabetes  remains  an important  health  problem with approximately one in  five 
male diabetics undiagnosed in 1999–2002.
Table 1.2: Different Forms of Diabetes Mellitus11
General—genetic and other factors not precisely defined
Type 1 diabetes mellitus (formerly called insulin-dependent DM)
Auto-immune type 1 DM (type 1A)
Non-autoimmune/idiopathic type 1 DM (type 1B)
Type 2 diabetes mellitus (formerly called non-insulin-dependent DM)
Specific—defined gene mutations
Maturity-onset diabetes of youth (MODY)
MODY 1 hepatic nuclear factor 4α (HNF4A) gene mutations
MODY 2 glucokinase (GCK) gene mutations
MODY 3 hepatic nuclear factor 1α (TCF1) gene mutations
MODY 4 insulin promoter factor 1 (IPF1) gene mutations
MODY 5 hepatic nuclear factor 1β (HNF1 β) gene mutations
MODY 6 neurogenic differentiation 1 (NEUROD1) gene mutation
MODY X unidentified gene mutation(s)
Maternally inherited diabetes and deafness (MIDD)
Mitochondrial leucine tRNA gene mutations
Insulin gene mutations
Insulin receptor gene mutations
Diabetes secondary to pancreatic disease
Chronic pancreatitis
Surgery
Tropical diabetes (chronic pancreatitis associated with nutritional and/or toxic factors)
Diabetes secondary to other endocrinopathies
Cushing's disease
Glucocorticoid administration
Acromegaly
Diabetes secondary to immune suppression
Diabetes associated with genetic syndromes; e.g., Prader-Willi syndrome
Diabetes associated with drug therapy
This is far less of a problem than 25 years ago, when almost half of male diabetics were 
undiagnosed. Although race and ethnic differentials in undiagnosed diabetes were eliminated over the 
last 25 years, the disparities became larger across other measures of disadvantage such as education. 
Undiagnosed diabetes is a particularly severe problem among the obese, a group at much higher risk of 
diabetes onset.12
 Cause11, 13, 14
In  certain  tropical  countries,  the  most  common  cause  of  diabetes  is  chronic  pancreatitis 
associated with nutritional or toxic factors (a form of secondary diabetes). Very rarely, diabetes results 
from point mutations in the insulin gene. Amino acid substitutions from such mutations may result in 
insulin with lower potency or may alter the processing of proinsulin to insulin.11
There are genetic and environmental components that affect the risk of developing either type 1 
or type 2 DM. There is considerable evidence that type 1 DM involves an autoimmune attack on the 
pancreatic β cell. Both Fas-dependent and -independent mechanisms are involved in β cell destruction, 
but interference with the Fas pathway early in disease development may retard or prevent diabetes 
progression. Studies have determined that the presence of antibodies directed against insulin (IAAs) 
confers only a small risk for the development of type 1 DM. On the other hand, the presence of high-
titer islet-cell antibodies (ICAs) and GAD antibodies or ICAs combined with IAAs confers a very high 
risk for the development of type 1 DM in first-degree relatives. Individuals with type 1 DM also tend to 
have antibodies directed toward other endocrine tissues, including the adrenal, parathyroid, and thyroid 
glands, and have an increased incidence of other autoimmune diseases.11, 13
The trigger for the immune response remains unknown. The identification of triggering agents 
is difficult because autoimmune destruction of pancreatic  β cells may occur over a period of many 
months or several years before the onset of overt disease. In about 10% of new cases of type 1 DM, 
there is no evidence of autoimmune insulitis. World Health Organization (WHO) therefore subdivides 
this disease into autoimmune (1A) and idiopathic (1B) subtypes. Whatever be the causes, the final 
result in type 1 DM is an extensive and selective loss of pancreatic  β cells and a state of absolute 
insulin deficiency.11
Patients with type 2 DM either have a decreased production of insulin by the  β cells of the 
pancreas or a decreased sensitivity of the cells to insulin, making the cells insulin resistant. Although 
type 2 DM may occur at any age, the disorder occurs most often after the age of 40 years. The onset of 
type 2 DM is usually insidious, symptoms are less severe than in type 1 DM, and because it tends to be 
more stable, it is easier to control than type 1 DM. Risk factors included in the screening guidelines 
have  a  strong association  with  diabetes.  Hypertension  or  positive  family histories  of  diabetes  can 
double the risk of having diabetes. 
Virtually all forms of DM are caused by a decrease in the circulating concentration of insulin 
(insulin deficiency) and a decrease in the response of peripheral tissues to insulin (insulin resistance). 
These abnormalities lead to alterations in the metabolism of carbohydrates, lipids, ketones, and amino 
acids; the central feature of the syndrome is hyperglycemia.11, 14
Risk factors for type 2 diabetes include:
• Obesity
• Older age
• Family history of diabetes
• History of  gestational  diabetes  (diabetes  that  develops  during  pregnancy but  disappears 
when pregnancy is over)
• Impaired glucose tolerance
• Minimal or no physical activity
• Race/ethnicity  (African  Americans,  Hispanic/Latino  Americans,  American  Indians,  and 
some Asian Americans)11
 Insulin11
Insulin is a hormone manufactured by the β cells of the pancreas. It is the principal hormone 
required for the proper use of glucose (carbohydrate) by the body. Insulin also controls the storage and 
utilization of amino acids and fatty acids. Insulin lowers blood glucose levels by inhibiting glucose 
production by the liver.
Figure 1.3: Normal Glucose Metabolism11
Insulin is available as purified extracts from beef and pork pancreas and is biologically similar 
to human insulin. However, these animal source insulins are used less frequently today than in years 
past. They are being replaced by synthetic insulins, including human insulin or insulin analogs. Human 
insulin is derived from a biosynthetic process using strains of  Escherichia coli  (recombinant DNA 
technique). Human insulin appears to cause fewer allergic reactions than does insulin obtained from 
animal sources. Insulin analogs, insulin lispro, and insulin aspart are newer forms of human insulin 
made by using recombinant DNA technology and are structurally similar to human insulin.
 Indications and Goals for Therapy11
Subcutaneous administration of insulin is the primary treatment for all patients with type 1 DM, 
for patients with type 2 DM that is not controlled adequately by diet and/or oral hypoglycemic agents, 
and for patients with postpancreatectomy diabetes or gestational diabetes. In addition, insulin is critical 
for  the  management  of  diabetic  ketoacidosis,  and  it  has  an  important  role  in  the  treatment  of 
hyperglycemic, nonketotic coma and in the perioperative management of both type 1 and type 2 DM. 
In all cases, the goal is to normalize not only blood glucose but also all aspects of metabolism; the latter 
is difficult to achieve. Optimal treatment requires a coordinated approach to diet,  exercise, and the 
administration of insulin.
1.4 CANCER15-20
Clinically, cancer is the name given to a large family of diseases, may be a hundred or more, 
which vary in age of onset, rate of growth, state of growth, state of cellular differentiation, diagnostic 
delectability, invasiveness, metastasis potential and response to treatment and prognosis. Cancer occurs 
when cells become abnormal and keep dividing and forming new cells. Normally, cells divide to form 
new cells only when the body needs them. If cells divide when new ones are not needed, they form a 
mass of excess tissue, called a tumor. Tumors can be benign (not cancer) or malignant (cancer).
The cells in the malignant tumors can damage and invade nearby tissues and organs. Cancer 
cells can also break away from the malignant tumor and travel through the bloodstream to form new 
tumors in other parts of the body. The spread of cancer is called metastasis. Over 1 million cases of 
cancer occur in the United States every year, not including basal cell and squamous cell skin cancers, 
which add another 700,000 cases annually. Although it is considered as a disease of aging, cancer can 
occur at any time. On average, the diagnosis of the most common types of cancer comes at about age 
67. Although cancer is relatively rare in children, it is still a leading cause of death between ages 1 and 
14. Millions of people alive today have had some type of cancer. Of these, about half are considered 
cured. The good news is that more and more people are now being cured of their cancers. This progress 
is due to better techniques of diagnosis and treatment.15
 Causes15
In many cases, the causes of cancer are not clear, but both external and internal factors play a 
role. Cigarette smoking is a major causal factor. Other than that, diet, genetic mutation, exposure to UV 
light and carcinogenic chemicals may also cause cancer.
 Prevention15
 The best way to reduce deaths from cancer is to prevent it. Medical doctors generally agree that 
about one-third of all human cancers are directly related to cigarette smoking. For smokers, the risk of 
cancer is much higher than that of the nonsmokers. Excluding the UV rays of sunlight which cause skin 
cancer, the next most common cited cancer-causing factor is diet. The National Cancer Institute and the 
American Cancer Society recommend a diet low in fat, high in natural fiber, and rich in fruits and 
vegetables. Chemoprevention on the other hand is simply prevention with drugs. The word “drugs” is 
used to include dietary supplements, hormones, and vitamins etc., as well as real drugs such as aspirin 
and other synthetic agents used for therapeutic purposes. The number of chemo preventive agents is 
increasing.
 Treatments15
Surgery is the oldest and still the most common treatment for cancer. Radiation therapy is the 
use of ionizing radiation to treat cancer. Ionizing radiation can be delivered using photon beams and 
particle beams. Radiation therapy is used at some point in the treatment of more than half of all cancer 
cases. High-energy X-rays are used to damage cancer cells and stop them from growing and spreading. 
It can be used to shrink a tumor before surgery, but it is often used after surgery. Like surgery it is a 
local treatment; it affects the cells only in the treated area. Hormone therapy is used to keep cancer 
cells  from getting  the  hormones  they  need  to  grow.  It  is  often  used  as  a  follow-up  to  surgery. 
Reconstructive surgery is when one part of the body is replaced with another part. Chemotherapy is the 
use of drugs to kill cancer cells. Unlike surgery and radiation therapy it is systemic; it works throughout 
the body. A single drug or a combination of drugs may be used. Chemotherapy is often used after 
surgery to kill any hidden cancer cells that remain in the body.
 Natural products in cancer chemotherapy16-20
Drugs from plants (natural product drugs) have played a dominant role in pharmaceutical care 
for the treatment of various diseases, especially cancer.  In addition to its use to treat heart failure, 
Nerium oleander;  Apocynaceae is also known to be toxic against a wide range of tumor cells.  The 
pentacyclic triterpenoids isolated from Nerium oleander; possess cytotoxic activity.  AnvirzelTM is an 
aqueous extract of the plant Nerium oleander which has been utilized to treat patients with advanced 
malignancies.  Teniposide a  chemical  analog of the natural  product  podophyllotoxin shows activity 
against Hodgkin’s disease and other malignant lymphomas,  pediatric refractory neuroblastoma, and 
brain  tumors  in  adults.  The  alkaloid  Camptothecin  was  first  isolated  from the  tree  Camptotheca 
acuminate. It has good activity against various cancers in the laboratory, but is too insoluble for clinical 
use. Various water-soluble analogs of Camptothecin (e.g. topotecan) have been developed, however, 
and have found significant clinical use. Some other plant species which are used in cancer therapies are 
Maytenus  buchananii,  Triptigium wilfordii,  Cephalotaxus  harringtonia. The  glycorandomization  of 
cardiac glycoside leads to analogs that display significantly enhanced potency and tumor specificity 
when  a  universal  chemical  glycosylation  method  that  employs  reducing  sugars  and  requires  no 
protection or activation is used. This suggests a divergent mechanistic relationship between cardiac 
glycoside  induced  cytotoxicity  and  Na+/K+-ATPase  inhibition. There  is  a  potential  of  chemical 
modification to  reduce  the cardiovascular  side-effects  and improve  the anti-cancer  activity of  new 
molecules. Ouabain and other cardiotonic steroids kill renal epithelial and vascular endothelial cells via 
their interaction with the Na+/K+-ATPase-subunit,  but independently of elevation of the [Na+]i/[K+]i 
ratio.
Figure 1.4: Mechanism of action of AnvirzelTM
1.5 ENDOPHYTIC FUNGI21-32
Microorganisms  have  long  served  mankind  by  virtue  of  the  myriad  of  the  enzymes  and 
secondary compounds that they produce. Furthermore, only a relatively small number of microbes are 
used directly in industrial applications (e.g. cheese, wine and beer making), in environmental clean-up 
operations and in the biological control of pests and pathogens. It seems that we have by no means 
exhausted the world of its hidden microbes, and a much more comprehensive search of the Earth’s 
various niches might yet reveal novel microbes which have direct usefulness to human societies. These 
uses could be either of the microbes itself, or one or more of its natural products.
The diversity of microbial life is enormous and the niches in which microbes live are truly 
amazing,  ranging  from  deep  ocean  sediments  to  the  Earth’s  thermal  pools.  The  diversity  of 
macroorganisms is probably mirrored by the diversity of microorganisms. That is, areas of the Earth 
inhabited by an enormous diversity of higher life forms are probably also inhabited by a high diversity 
of microorganisms. One specialized and unique biological niche that supports the growth of microbes 
is the intracellular space between cells of higher plants. It turns out that each plant supports a suite of 
microorganisms known as endophytes.  These microorganisms do not cause overt  symptoms on the 
plants in which they live. Furthermore, because so little work on these endophytes has been done, it is 
suspected that untold numbers of novel fungal and bacterial genera exist as plant-associated microbes 
and their diversity might parallel that of the higher plants. Such a specific search is governed by the 
fact that some endophytes could have coevolved with their respective higher plant and, as a result, 
already exist compatibly with a higher life-form. Thus, we have begun a concerted search for novel 
endophytic microbes, with the prospect that they could produce novel bioactive products as well as 
possess processes that might prove useful.
It is obvious that any discovery of novel microbes will have implications in virtually all of the 
standard processes of industrial microbiology because scale-up fermentation of the microbe will be 
necessary.21
A variety of animals and plants bear symbiotic microorganisms that contribute to their nutrition 
or defense against predators and parasites. These relationships are widely considered as mutualistic, i.e. 
both  the  animal/plant  host  and  the  microbial  symbiont  from  the  association.  By  definition,  an 
endophytic fungus lives in mycelial form in biological association with the living plant, at least for 
some time. Therefore the minimal requirement before a fungus is termed an ‘endophyte’ should be the 
demonstration of its hypha in living tissue. Some species of endophytic fungi have been identified as 
sources  of  anticancer,  antidiabetic,  insecticidal  and  immunosuppressive  compounds.  Further, 
endophytic fungi may also produce metabolites with thermo protective role.22-24
 Isolation of Endophytic Fungi
It is important to establish a specific protocol for the isolation of endophytes from a given plant, 
particularly as  90-99% of  microorganisms are  not  readily cultivable.  The  most  frequently isolated 
microorganisms are endophytic fungi. Scrutiny of the literature shows that there is little difference in 
the frequency of success of various isolation protocols, and that standardized procedures inevitably fall 
to result in the isolation of certain special endophyte(s).25
• Methods for the Isolation of Endophytes
The method most frequently utilized method to detect and quantify endophytic fungi involves 
isolation from surface-sterilized host plant tissue. For reports profiling inventors of endophyte species 
occurrence  and diversity,  this  is  currently the  most  practiced  approach,  although fungal  biologists 
recognize that some endophyte groups may be undetected or under-represented,  and in particulate, 
isolated that are unable to sporulate in culture may need to be evaluated by other means, host species, 
sampling strategy, host-endophyte and inter-endophyte interactions, tissue types and ages, geographic 
and  habitat  distributions,  types  of  fungal  colonization,  culture  conditions,  surface  sterilants,  and 
selective media all influence the detection and enumeration of endophytic fungi, techniques used for 
isolation, maintenance, identification, and preservation of all endophytic fungus.
Detailed practical information on methods for the isolation of filamentous fungi from various 
substrata,  including  techniques,  selective  agents,  and  the  most  common media,  is  available  in  the 
literature. Surface sterilization of plant material is usually accomplished by treatment with a strong 
oxidant or general disinfectant for a period, followed by a sterile rinse. Household bleach (NaOCl), 
usually diluted in water  to concentrations of 2-10% is  the most  commonly used surface sterilants. 
Similarly effective  oxidants  include  3%H2O2 and  2%KMnO4.  Furthermore,  the  efficacy of  surface 
sterilization can be substantially improved by combining with a  wetting agent.  This is  particularly 
appropriate for hydrophobic or densely pubescent leaves. Ethanol (70-95%) is the most commonly used 
wetting agent in this respect, however, it has limited antibiotic activity, and thus is not used alone as a 
surface disinfectant. Other surfactants such as tween 80 have found use as wetting agents to enhance 
surface sterilization of the host plants.25
 
• Isolation Procedures
The host  plant  should be unambiguously identified  in  any endophyte-related study,  and its 
global position, as defined by location, latitude, longitude and altitude, should be recorded. Endophytes 
are  generally  isolated  after  cutting  individual  plant  organs  into  segments  (3-5  mm long)  followed 
immediately by treatment with bleach. Alternatively, plant material is surface treated with 70% ethanol 
and then dried under a laminar flow hood, two to three tissue segments are removed every 2-3 minutes 
and vigorously rinsed in sterile distilled water.
These pieces then are pressed into potato dextrose agar (PDA), and the plates are incubated at 
room temperature for 3-4 weeks. Rapidly growing fungi that appear within the first two weeks are 
generally discarded since they are most probably contaminants. After 2-4 weeks, white to off- white 
colonies of endophytes become visible.
Plates are prepared in triplicate to eliminate the possibility of contamination or heterokaryosis. 
It is advisable to remove outer tissues with a sterile knife blade, and the newly formed surfaces are 
placed carefully onto agar plates or PDA medium co-supplemented with 200 µg/ml ampicillin and 200 
µg/ml streptomycin to suppress bacterial growth until the mycelium or colony originating from the 
segments appears. After several days of incubation, hyphal tips of the fungal endophyte are removed 
and transferred to newly prepared PDA plates. Some bacterial species such as  streptomyces  spp. can 
survive this  treatment.  For identification purposes,  the endophytes  are  trained to  sporulate  on pre-
treated plant materials.
In order to isolate endophytes from plant seeds, the deglume is required to be removed together 
with contaminants associated with the dry glumes. This is achieved by rubbing the seeds vigorously 
between the hands and then rinsing the seeds for 15-20 minutes with a bleach solution. The isolation of 
endophytic bacteria is often accomplished by pasting onto nutrient agar plates the trituration of plant 
tissues surface-disinfected with various disinfectants such as sodium hypochlorite, ethanol, hydrogen 
peroxide, mercuric chloride, or a combination of two or more of these.25, 26
 Identification
Rigorous identification of endophytes requires microscopic examination of the host tissue and 
relies to a significant extent on the taxonomic expertise of the examiner. Morphological examination is 
performed by scrutinizing the culture, the mechanism of spore production, and the characteristics of the 
spores.  This  is  especially  valuable  for  isolates  failing  to  produce  spores  or  identifiable  structures. 
Sometimes, optimization of growth conditions aiming at inducing sporulation of endophytes is a trial-
and-error process. Each of the isolated fungal strains is  separately inoculated on PDA, CMA, CA, 
WSA  and  PCA  media  in  Petri  dishes  to  achieve  optimum conditions  for  sporulation.  Moreover, 
endophytic fungi that neither grow nor sporulate in culture can only be detected and identified by other 
means such as a comparison of ribosomal DNA (rDNA) gene sequences, an analysis that can be used to 
determine phylogenic relationships.
Accordingly, endophytic isolates are often identified using a combination of morphological and 
molecular methods. Special caution has to be taken when closely related or morphologically similar 
endophytic  fungi  are  under  identification.  The  morphological  features  of  some  fungi  are  usually 
medium  dependent,  and  some  cultural  conditions  can  affect  substantially  vegetative  and  sexual 
incompatibility. Thus, the morphological character of endophytes should be coupled with the available 
molecular evidence to  enable significant differentiation between closely related species.  For newly 
discovered endophytic fungi, morphology-based identification is confirmed by 18S rDNA sequence 
comparisons or internal transcribed spacer (ITS1 and ITS2) and 5.8S rDNA sequence examinations. An 
endophytic isolate from the roots of vascular plants was characterized on the basis of cultural  and 
morphological properties and PCR/RFLP analysis of the ITS region and a portion of the 28S subunit of 
rDNA.27
 Endophytes: a rich source of functional metabolites
In the continual search by both pharmaceutical and agricultural industries for new products, 
natural  selection  has  been  found  to  be  superior  to  combinatorial  chemistry  for  discovering  novel 
substances that have the potential to be developed into new industrial products. Since natural products 
are  adapted  to  a  specific  function  in  nature,  the  search  for  novel  secondary  metabolites  should 
concentrate on organisms that inhabit novel biotopes. Endophytic fungi inhabit such a biotope. In the 
course of the last 12 years, 6500 endophytic fungi were isolated from herbaceous plants and trees, 
screened for biological activities, and isolated and determined the structures of the biologically active 
compounds.
The substances isolated originated from different biosynthetic pathways: isoprenoid, polyketide, 
amino acid  derivatives,  and  belonged to  diverse  structural  groups:  terpenoids,  steroids,  xanthones, 
chinones,  phenols,  isocumarines,  benzopyranones,  tetralones,  cytochalasines,  and  enniatines.  The 
potential role of the endophyte and its biologically active metabolites in its association with its host has 
been investigated. The concentrations of some plant defense metabolites are lower than in the control 
when the host is infected with a pathogen than with an endophyte. 
The number of secondary metabolites produced by fungal endophytes is larger than that of any 
other endophytic microorganism class. This may of course be a consequence of the high frequency of 
isolation of fungal endophytes from plants. Natural products from fungal endophytes have a broad 
spectrum of biological activity, and they can be grouped into several categories, including alkaloids, 
steroids, terpenoids, isocoumarins, quinones, phenylpropanoids and lignans, phenol and phenolic acids, 
aliphatic metabolites, lactones, etc.25, 28
 The Global Importance of Endophytic Fungus Derived Drugs
Endophytes  are  the  source  of  a  broad  range  of  bioactive  metabolites,  such  as,  antibiotics, 
antiviral, anticancer, antioxidant, insecticidal, antidiabetic, immunosuppressive compounds. There is a 
high diversity, spatial structure, and host affinity among foliar endophytes associated with a tropical 
tree (Theobroma cacao, Malvaceae) across lowland Panama. The  inoculation of endophyte-free leaves 
with endophytes isolated frequently from naturally infected, asymptomatic hosts significantly decreases 
both leaf necrosis and leaf mortality when  T. cacao  seedlings are challenged with a major pathogen 
(Phytophthora sp.). In contrast to reports of fungal inoculation inducing systemic defense, it was found 
that  protection  was  primarily  localized  to  endophyte-infected  tissues.  Further,  endophyte-mediated 
protection was greater in mature leaves, which bear less intrinsic defense against fungal pathogens than 
do young leaves.  In vitro  studies suggest that host affinity is mediated by leaf chemistry,  and that 
protection may be mediated by direct interactions of endophytes with foliar pathogens. Together, these 
data demonstrate the capacity of diverse, horizontally transmitted endophytes of woody angiosperms to 
play an important but previously unappreciated role in host defense.29, 30
Endophytes  isolated from rice (Oryza sativa)  used as  the  test  plant  produced two types  of 
interactions; biofilms (bacteria attached to mycelia) and mixed cultures with no such attachments.31
Fungal endophytes were isolated from roots and leaves of epiphytic and lithophytic orchids in 
the genus  Lepanthes; seven species, from rainforests in Puerto Rico, were sampled. The endophytes 
observed most frequently were Xylaria species and Rhizoctonia-like fungi, found in 29%of roots and 
19%of leaves, and 45%of roots and 31%of leaves, respectively. Five deuteromycete genera were also 
isolated, occurring in 19%of roots and 43%of leaves (combined). At least nine species of Xylaria were 
found, with several species sometimes occurring in a single plant.32
2. PLANT PROFILE 16, 17, 33-47
2.1 GENERAL INFORMATION
Figure 2.1 Flowering Twing of Nerium oleander
Kingdom  Plantae
Division  Magnoliophyta
Class  Magnoliopsida
Order  Gentianales
Family  Apocynaceae (dogbane)
Genus  Nerium L.
Species  N. oleander
Scientific name Nerium Oleander Linn.
Common Names Oleander, adelfa, laurier rose, rosa laurel, rose bay, rosa francesa.33
 Origin and distribution
Nerium  oleander  Linn  distributed  in  the  Mediterranian  region  and  sub-tropical  Asia  is 
indigenous to the Indo-Pakistan subcontinent. It is a native to a broad area from Morocco and Portugal 
eastward through the Mediterranean region and southern Asia to Yunnan in southern parts of China. 
The plant is also found commonly in the southern United States and most of California.33, 34
Form Large shrub can be trained to single or multi stemmed tree
Seasonality evergreen 
Size large variation with cultivars; heights from 3 to 20ft, spreads from 3-12ft 
Leaves simple,  linear,  3-12in long,  whorled around stem,  glossy dark green on top and 
lighter underneath with prominent mid-rib 
Flowers Terminal  clusters,  may be yellow,  white,  pink or  red;  may be single or  double; 
bloom in spring and throughout summer 
Fruit 3-5in long pods, green ripening to brown, splits to release airborne seed 
Stems/Trunks gray, extremely tough, can be trained or pruned as desired 
Range/Origin Mediterranean and Asia 
Hardiness varies  with  variety,  standard  types  to  low  teens,  dwarf  varieties  more  tender; 
damage seen on dwarfs in high teens; all types recover quickly from frost damage33, 
34
2.2 CULTIRAL REQUIREMENTS33
Exposure  full sun to part shade, takes reflected heat
Water  drought tolerant; supplement during hot season, 
Soil  tolerant, good drainage 
Propagation  vegetative cuttings 
Maintenance  low to moderate; pruning to control size or shape
2.3 FOLKORIC USES
• Herpes zoster (skin): Crush leaves, mix oil and apply on lesions. Do not apply on raw surface. 
Milky juice of the plant is irritating. Caution: Not to be taken internally.
• Herpes simplex: Mix 1 cup of chopped leaves and bark with 2 tablespoons of oil. Apply to 
lesions 3 times daily.
• Ringworm: Chop a foot long branch and mix with 1 cup chopped fresh young leaves. Mix the 
juice with 5 drops of fresh coconut oil. Apply 3 times daily.
• Snake bites: Pound 10 leaves and a piece of branch. Apply poultice to the wound.
• Roots, locally and internally, used for abortion.
• Roots, made into paste with water, used for hemorrhoids.
• Roots and bark externally for eczema, snake bites and as insecticide.
• Fresh leaves applied to tumors to hasten suppuration.33
2.4 CHEMICAL CONSTITUENTS
Nerium  oleander's  leaves  contain  two  principles:  neriin  and  oleandrin,  glucosides  with 
properties similar to digitalin. The seeds contain phytosterin and l-strophnathin. The bark contains toxic 
glycosides: rosaginin and neriin, volatile oil, fixed oil. Various parts of the plant are known to yield 
cardenolides,  pregnanes  and  triterpenes. The  evidence  of  isolation  of  two  cytotoxic  pentacyclic 
triterpenoids,  cardenolide  (3b-hydroxy-5b-carda-8,  14,  16,  20(22)-tetraenolide)  and  four  CNS 
depressant  cardenolides  including a  new cardenolide,  neridiginoside  and three  known constituents, 
nerizoside, neritaloside and odoroside-H, which exhibited CNS depressant activity in mice  from the 
leaves of N. oleander, is found in literature. Kaneroside and neriumoside have been isolated from the 
fresh,  undried,  winter  leaves  of  Nerium  oleander.  Polar  glycosides  gentiobiosyl-nerigoside  and 
gentiobiosylbeaumontoside are isolated along with the major trioside, gentiobiosyl-oleandrin from air 
dried  Nerium oleander leaves. Neritaloside, oleandrigenin, odoroside, and oleandrin are detected by 
HPLC/MS/MS from a novel oleander extract. Oleandrin production can be enhanced by tissue culture 
technique.16, 34-39
2.5 MEDICINAL USES
(Cancer; Cardiotonic; Diaphoretic; Diuretic; Emetic; Expectorant; Resolvent; Skin; Sternutatory)
The  leaves  and  the  flowers  are  cardiotonic,  diaphoretic,  diuretic,  emetic,  expectorant  and 
sternutatory. The crude ethanolic extract of Nerium oleander possesses cardiotonic effect in the isolated 
guinea pig hearts. A decoction of the leaves has been applied externally in the treatment of scabies, and 
to reduce swellings. This is a very poisonous plant, containing a powerful cardiac toxin, and should 
only be used with extreme caution. The root is powerful resolvent. Because of its poisonous nature it is 
only used externally. It is beaten into a paste with water and applied to cancers and ulcers on the penis. 
Oil prepared from the root bark is used in the treatment of leprosy and skin diseases of a scaly nature. 
The whole plant is said to have anticancer properties.
AnvirzelTM is an aqueous extract of the plant Nerium oleander which has been utilized to treat 
patients with advanced malignancies. Topical application of oleandrin possesses anti-tumor promoting 
effects. Oleandrin suppresses activation of nuclear transcription factor-κB and activator protein-1 and 
potentiate apoptosis induced by ceramide.
Treatment of Streptozotocin-Induced diabetic rats with glimepiride and Nerium oleander extract 
offered protection in terms of lipid profile, growth rate and renal function, indicating their antidiabetic 
potential.
Extract  obtained  from  Nerium  oleander  has  in  many  cases  significantly  prolonged  life  of 
patients with metastatic cancer disease.40-44
2.6 OTHER USES
(Dye; Hedge; Insecticide; Latex; Parasiticide; Soil stabilization)
The plant is used as a rat poison, a parasiticide and an insecticide. The pounded leaves and bark 
are used as an insecticide. A green dye is obtained from the flowers.  The plant extracts is used as a 
wood preservative due to its antifungal properties.45
2.7 TOXICITY
Oleandrin ingested in small quantities (0.005% animal weight in horse) cause death. Oleander 
bark contains rosaginin which is known for its strychnine-like effect. The entire plant including the 
milky white sap is toxic and any part can cause an adverse reaction. Oleander holds its toxicity even 
after drying. The literature review indicates that small children and domestic livestock are at increased 
risk of oleander poisoning. According to Toxic Exposure Surveillance System (TEES) in 2002 there 
were 847 known human poisonings in the United States related to oleander. There are innumerable 
reported suicidal cases of consuming mashed oleander seeds in South India. In animals, 0.5 mg/kg of 
body weight is lethal to many animals.
In  cases  of  digitalis-like  poisoning  with  suspicion  of  oleander  ingestion,  a  combination  of 
digoxin immunoassays may be useful to effectively rule out the presence of oleander.31, 46
1. LITERATURE REVIEW
1. John P. Reeves et. al., (1979)48 isolated membrane vesicles from rabbit ventricular tissue rapidly 
accumulated  Ca2+ when  an  outwardly  directed  Na+  gradient  was  formed  across  the  vesicle 
membrane.  Vesicles  loaded  internally  with  K+ showed  only  10%  of  the  Ca2+  uptake  activity 
observed with Na+-loaded vesicles. Na+-dependent uptake and efflux of Ca2+ were both inhibited by 
La3+.  The  results  indicate  that  cardiac  membrane  vesicles  exhibit  Na+-Ca2+ exchange  activity. 
Fractionation of the vesicles by density gradient centrifugation revealed a close correspondence 
between  Na+-Ca2+ exchange  activity  and  specific  ouabain-binding  activity  among  the  various 
fractions. This relationship suggests that the observed Na+-Ca2+ exchange activity derives from the 
sarcolemmal membranes within the vesicle preparation.
2. B.  Chiarlo  et.  al.,  (1978)55 evaluated  the  oleandrin  content  of  leaves  of  Nerium oleander  L. 
monthly,  over a period of 15 months, by a spectrophotometric method after  solvent extraction, 
chromatographic separation on silica gel preparative/avers and column purification. The amount of 
oleandrin is connected with the cambium meristem rhythm of the stem during different months of 
the year. It has been shown that the increase of oleandrin content is connected with the cambium 
reactivation which, in turn, is affected by the weather conditions.
3. Bina S. Siddiqui et. al., (1987)36 isolated two new cardiac glycosidcs, kaneroside and ncriumoside, 
from the fresh, undried, winter leaves of Nerium oleander and their structures established as 3~-O-
(D-diginosyl~Zz-hydroxy-8.14~3poxy-S~car&-16:  17,20:22dicnolide  and  3/3-O-
(Ddiginosyl)-2x,l4/3dihydroxy-Sgcard-l6:  l7,20:22dicnolide,  respectively,  through  chemical  and 
spectral studies.
4. Naci  M.  Bor  et.  al.,  (1988)44 claimed  that  the  extract  obtained  from  Nerium  Oleander  has 
significantly prolonged life of patients with metastatic cancer disease where regression has been 
observed in some cases and total cure in others. Immunomodulator function observed by Roemer 
may explain  the  improvement  recorded  in  many of  them.  These  reports,  however,  have  been 
opposed by others  who maintain  that  besides  the  extract  being  toxic  the  evidence  in  favor  of 
Nerium Oleander's benefical influence on cancer is insufficient. Still others have collected evidence 
indicating that it is in proposed doses nontoxic.
5. Fumiko  Abe  et.  al.,  (1992)37 isolated  gentiobiosyl-nerigoside  and  gentiobiosyl  beaumontoside 
along with the major trioside, gentiobiosyl-oleandrin from the air-dried leaves of Nerium oleander. 
Minor triosides also include glycosides of 8/l-hydroxy-  and A16-8fi-hydroxy-digitoxigenin,  and 
Ai6  -neriagenin,  along  with  glycosides  of  known  cardenolides,  oleandrigenin,  digitoxigenin, 
adynerigenin, neriagenin and their A16-derivatives.
6. Bina S. Siddiqui et. al., (1995)16 described the isolation and structure elucidation of two novel 
cytotoxic pentacyclic triterpenoids cis-karenin (3fl-hydroxy-28-Z-p-coumaroyloxy-urs-12-en-27-oic 
acid) and trans-karenin (3-fl-hydroxy-28-E-p-coumaroyloxyurs-12-en-27-oic acid) from the leaves 
of Nerium oleander.
7. Roland Valdes, Jr. et. al.,  (1996)47 have investigated the cross-reactivities of oleandrin and its 
aglycone  metabolite,  oleandrigenin,  in  several  commercially  available  digoxin  immunoassays; 
assessed  their  ability  to  inhibit  Na,K-ATPase  catalytic  activity;  and  measured  their  binding  to 
proteins in serum. As assayed with ACS: 180, Stratus, RIA, On-Line, and TDx digoxin assays, 
oleandrin at 100 Lmol/L in digoxin-free serum gave apparent digoxin values of 0, 0.83, 2.24, 2.37, 
and 5.34 nmolfL, respectively, whereas oleandrigenin at that concentration gave results of 0, 0.52,  
0.77,4.94, and 1.40 nmol/L. Study of Na,K-ATPase inhibition showed IC50 values (Lmol/L) of 
0.22  for  ouabain,  0.62  for  oleandrin,  1.23  for  oleandrigenin,  and  2.69  for  digoxin.  At 
25{17966}%C, of oleandrin and 48% of oleandrigenin were bound to serum proteins. In cases of 
digitalis-like  poisoning  with  suspicion  of  oleander  ingestion,  a  combination  of  digoxin 
immunoassays may be useful to effectively rule out the presence of oleander.
8. C.M. Hasan et.  al.,  (1999)35 isolated  a new cardenolide,  12b-hydroxy-5b-carda-8,14,16,20(22)-
tetraenolide (2) from the roots of Nerium oleander. Biological screening of the compound revealed 
antibacterial and digoxin-like cardiac activities.
9. Bina S. Siddiqui et. al., (1999)34 studied the central nervous system (CNS) depressant effect in 
mice of a bioactivity directed isolation of the methanolic extract of the fresh, uncrushed leaves of 
Nerium oleander.  As  a  result,  four  CNS depressant  cardenolides  including  a  new cardenolide, 
neridiginoside and three known constituents, nerizoside, neritaloside and odoroside-H, have been 
isolated which exhibited CNS depressant activity in mice at a dose of 25 mg/kg. The structure of 
neridiginoside was elucidated as 3b-O- (D-diginosyl)-5b,14b-dihydroxy-card-20(22)-enolide, using 
spectroscopic methods including one-dimensional and two-dimensional NMR (COSY-45, NOESY, 
J-resolved,  HMQC and HMBC).  The known compounds have been identified  through spectral 
studies and comparison of data with those reported in the literature.
10. Xiaomin Wang et. al., (2000)38 have developed an HPLC/MS/MS method for the characterization 
and quantification of the cardiac glycosides oleandrin,  odoroside,  neritaloside and the aglycone 
oleandrigenin, all contained in a patented-hot-water extract of Nerium oleander L (Anvirzel), using 
a  hybrid  tandem  quadrupole  time-of-flight  (QqTOF)  mass  spectrometer.  Collision-induced 
dissociation  (CID)  mass  spectra  of  oleandrin,  oleandrigenin,  odoroside,  and  neritaloside  were 
obtained with greater than 5 ppm mass accuracy and resolution routinely in excess of 8000 (fwhm). 
The detection limit for oleandrin of 20 pg (injected) was realized when the precursor-to-product ion 
transition,  m/z  577  f  373,  was monitored.  They have also applied the analytical  method to  the 
determination of oleandrin, oleandrigenin, neritaloside, and odoroside in human plasma following 
an intramuscular injection of Anvirzel.
11. Christopher  M.  M.  Franco  et.  al.,  (2003)52 isolated  filamentous  actinobacteria  from surface-
sterilized root tissues of healthy wheat plants (Triticum aestivum L.). Roots were surface-sterilized 
by using ethanol and sodium hypochlorite prior to the isolation of the actinobacteria. Forty-nine of 
these  isolates  were  identified  by using  16S ribosomal  DNA (rDNA) sequencing  and found to 
belong  to  a  small  group  of  actinobacterial  genera  including  Streptomyces,  Microbispora, 
Micromonospora, and  Nocardiodes  spp. In particular, several isolates exhibited high 16S rDNA 
gene sequence homology to Streptomyces caviscabies and S. setonii. None of these isolates, nor the 
S. caviscabies  and  S. setonii  type strains, were found to carry the  nec1  pathogenicity-associated 
gene or to produce the toxin thaxtomin, indicating that they were nonpathogenic. These isolates 
were  recovered  from  healthy  plants  over  a  range  of  geographically  and  temporally  isolated 
sampling events and constitute an important plant-microbe interaction.
12. R. O. Adome et. al., (2003)40 have tested the crude ethanolic extracts of the dried leaves of Nerium 
Oleander  against the following parameters in the isolated guinea pig hearts: force of contraction, 
heart  rate  and  cardiac  flow.  The  extracts  brought  about  dose-dependent  increases  in  all  these 
parameters from their baseline readings. Compared with graded doses of digoxin the effects closely 
mirrored the activities in a dose dependent manner. At the mechanism of action level, it would 
appear the extract works in the same as digoxin since their dose-contraction reponse curves are 
parallel.  This finding would tend to provide a strong rationale  for the herb’s traditional use in 
cardiovascular illness.
13. R.X. Tan et. al., (2004)50 recognized Aspergillus fumigatus CY018 as an endophytic fungus for the 
first time in the leaf of Cynodon dactylon. By bioassay-guided fractionation, the EtOAc extract of a 
solid-matrix steady culture of this fungus afforded two new metabolites, named asperfumoid (1) 
and asperfumin (2), together with six known bioactive compounds including monomethylsulochrin, 
fumigaclavine C, fumitremorgin C, physcion, helvolic acid and 5,8-epidioxy-ergosta-6,22-diene-3-
ol as well as other four known compounds ergosta-4,22-diene-3-ol, ergosterol, cyclo(Ala-Leu) and 
cyclo(Ala-Ile). Through detailed spectroscopic analyses including HRESI-MS, homo- and hetero-
nuclear  correlation NMR experiments (HMQC, COSY, NOESY and HMBC), the structures of 
asperfumoid and asperfumin were established to be spiro-(3-hydroxyl-2,6-dimethoxyl-2,5-diene- 4-
cyclohexone-(1,3)-5-methoxyl-7-methyl-(1H,  2H,  4H)-quinoline-2,4-dione)  and  5-hydroxyl-2-(6-
hydroxyl-2-methoxyl-4-methylbenzoyl)-3,6-dimethoxyl-benzoic  methyl  ester,  respectively.  As  a 
result, asperfumoid, fumigaclavine C, fumitremorgin C, physcion and helvolic acid were shown to 
inhibit C. albicans with MICs of 75.0, 31.5, 62.5, 125.0 and 31.5 g/mL, respectively.
14. R. Ananthan et. al., (2004)60 investigated the effect of Gymnema montanum leaf extract (GLEt) on 
tissue  antioxidant  defense  systems  in  alloxan-induced diabetes  in  rats. GLEt was  administered 
orally at doses of 50, 100, and 200 mg/kg of body weight for 30 d, after which liver and kidney 
tissues were assayed for the degree of lipid peroxidation by means of markers, reduced glutathione 
content and activities of catalase, superoxide dismutase, glutathione peroxidase, and glutathione-S-
transferase. Treatment of diabetic rats with GLEt increased the antioxidant levels. Liver and kidney 
from diabetic animals exhibited disturbances in antioxidant defense when compared with normal 
rats. GLEt at a dose of 200 mg/kg of body weight exhibited a significant effect as compared with 
50 and 100 mg/kg of body weight. These effects were compared with glibenclamide, a reference 
drug. They concluded that, in diabetes, liver and kidney tissues are more vulnerable to oxidative 
stress  and  show  increased  lipid  peroxidation.  The  antioxidant  responsiveness  mediated  by  G. 
montanum may be anticipated to have biological significance in eliminating reactive free radicals 
that may otherwise affect normal cell functioning and provide a scientific rationale for the use of G. 
montanum as an antidiabetic plant.
15. Sergei N. Orlov  et. al., (2005)20 reported that ouabain and other cardiotonic steroids (CTS) kill 
renal epithelial and vascular endothelial cells via their interaction with the Na+/K+-ATPase-subunit, 
but independently of elevation of the [Na+]i/[K+]i ratio. They did not observe any effect of extra- 
(EGTA)  and  intracellular  (BAPTA)  Ca2+-chelators,  [Ca2+]i-raising  compounds  (thapsigargin, 
ATP),  inhibitors  of  Ras  signaling  (hydroxyfarnesylsulphosphoric  acid),  PI3K  (wortmannin), 
MAPK ERK1/2 kinase (PD98059), tyrosine kinases (genistein) as well as activators (4-PMA,8-Br-
cAMP, 8-Br-cGMP, forskolin)  and  inhibitors  (calphostin)  of  serine–threonine  kinases  on MTT 
staining and death of ouabain-treated cells.  Ouabain did not  affect  cellular  redox state and the 
production of superoxide anion and hydroperoxide. Their results show that none of the above-listed 
signaling systems plays a major role in the development of Na+i ,K+i -independent death machinery 
triggered by CTS interaction with the Na+,K+-ATPase-subunit.
16. Jerry B Lingrel et. al., (2005)9 showed that binding site for cardiac glycosides in Na+/K+-ATPase 
plays  an  important  role  in  the  regulation  of  blood  pressure,  and  it  specifically  mediates 
adrenocorticotropic  hormone  (ACTH)-induced  hypertension  in  mice.  They  used  genetically 
engineered mice in which the Na+/K+-ATPase 2 isoform, which is normally sensitive to cardiac 
glycosides,  was  made  resistant  to  these  compounds.  Chronic  administration  of  ACTH  caused 
hypertension in WT mice but not in mice with an ouabain-resistant 2 isoform of Na+/K+-ATPase. 
Their results demonstrate that the cardiac glycoside binding site of the isoforms of the Na+/K+-
ATPase have a physiological function and supports the hypothesis for a role of the endogenous 
cardiac glycosides.
17. William J. Welsh et. al., (2005)8 proposed a binding mode for digoxin and several analogues to the 
Na+/K+-ATPase. A 3D-structural model of the extracellular loop regions of the catalytic a1-subunit 
of the digitalis-sensitive sheep  Na+/K+-ATPase was constructed from the crystal structure of an 
E1Ca2+ conformation  of  the  SERCA1a  and  a  consensus  orientation  for  digitalis  binding  was 
inferred from the in silico docking of a series of steroid-based cardiotonic compounds. Analyses of 
species-specific enzyme affinities for ouabain were also used to validate the model and, for the first 
time, propose a detailed model of the digitalis binding site.
18. Tarek Mekhail et. al., (2006)17 reported a phase 1 trial to determine the maximum tolerated dose 
(MTD)  and  safety  of  AnvirzelTM in  patients  with  advanced,  refractory  solid.  Patients  were 
randomized to receive this agent by intramuscular injection at doses of 0.1, 0.2, 0.4 ml/m2/day with 
subsequent patients receiving 0.8 or 1.2 ml/m2/day sequentially. Eighteen patients were enrolled 
and completed at least one treatment cycle of three weeks. Most patients developed mild injection 
site pain (78%). Other toxicities included fatigue, nausea, and dyspnea. Traditional dose limiting 
toxicity  was  not  seen,  but  the  MTD was  defined  by  injection  volume  as  0.8  ml/m2/day.  No 
objective anti-tumor responses were seen. AnvirzelTM can be safely administered at doses up to 1.2 
ml/m2/day, with the amount administered intramuscularly limited by volume. The recommended 
phase II dose level is 0.8 ml/m2/day.
19. Katarina Popov-Pergal et. al., (2006)61 synthesized new functionally substituted 5-arylidene-2,4-
dioxotetrahydro-1,3-thiazole-3-carboxylic  acid  cholesteryl  esters  from  2,4-dioxotetrahydro-1,3-
thiazole and evaluated for their in vitro cytotoxicity against several human tumor cell lines and one 
normal lung fibroblast cell line.
20. Maged M. Yassin et.  al.,  (2007)43 studied  the protective  potential  of  glimepiride  and Nerium 
oleander extract on lipid profile, body growth rate, and renal function in streptozotocin-induced 
diabetic rats. The animals were divided into control and experimental groups. The experimental 
group was rendered diabetic by intraperitoneal injection of a single dose of 50 mg/kg body weight 
streptozotocin. Rats with glucose levels >200 mg/dl were subdivided into 3 sub-groups. Rats in the 
first sub-group remained without treatment and were considered diabetic. Those in the second and 
third subgroups were orally administered 0.1 mg/kg body weight daily glimepiride and 250 mg/kg 
body weight daily Nerium oleander extract, respectively, for 4 weeks. In the streptozotocin induced 
diabetic rats, serum triglycerides and cholesterol were significantly increased whereas body growth 
rate was markedly decreased compared to the controls. In contrast to uric acid and creatinine, urea 
concentrations were markedly elevated. Treatment of diabetic rats with glimepiride or plant extract 
improved all of these parameters, indicating their antidiabetic efficacy.
21. Gary Strobel  et. al., (2007)51 isolated a novel endophytic fungal genus  Muscodor  that produces 
bioactive volatile organic compounds (VOCs). This fungus, as well as its VOCs, has enormous 
potential for uses in agriculture,  industry and medicine.  Muscodor albus  produces a mixture of 
VOCs that  act  synergistically to  kill  a  wide variety of  plant  and human pathogenic fungi  and 
bacteria. This mixture of gases consists primarily of various alcohols, acids, esters, ketones and 
lipids. Artificial mixtures of the VOCs mimic the biological effects of the fungal VOCs when tested 
against  a  wide  range  of  fungal  and  bacterial  pathogens.  Many  practical  applications  for 
‘mycofumigation’ by M. albus have been investigated and the fungus is now in the market place.
22. Ramesh Chandra et. al., (2007)59 studied the contribution of oxidative stress from the standpoint 
of lipid and protein damage, alteration in endogenous antioxidant enzymes and effects of newly 
synthesized  compounds,  5-[4-2-(6,7-Dimethyl-1,2,3,4-tetrahydro-2-oxo-4-
quinoxalinyl)ethoxy]phenyl]methylene]thiazolid-  ine-2,4-dione,  (C1)  in  normal/alloxan-induced 
diabetic  rats.  Its  effect  was  compared  to  two  well-known  TZDs,  namely  pioglitazone  and 
rosiglitazone. It has been concluded from results that after thirty days of administration of C1, Pg 
and  Rg  in  alloxan-induced  diabetic  animal  groups,  the  blood  glucose  level  decreased,  more 
remarkably in C1 treated group. Their results suggest that the newly synthesized TZD derivative 
(C1)  has  a  potential  to  act  as  antihyperglycemic  and  antioxidant  agent.  In  addition,  for  all 
parameters checked, it has better efficacy than rosiglitazone and is as effective as pioglitazone.
23. Mostafa Mesbah et.  al.,  (2007)39 established  suspension cultures  derived from  Agrobacterium 
tumefaciens-transformed calli in Nerium oleander  L. The presence of the bacterial T-DNA in the 
transformed  calli  was  detected  by  the  polymerase  chain  reaction  as  well  as  plant  hormone 
autotrophy.  The  ability  of  the  cultures  to  accumulate  oleandrin  was  confirmed  using  high 
performance liquid chromatography. The oleandrin yield reached a maximum of 3.164 mg l−1 in 
25-days upon employing A. niger elicitors. It was 8.8-fold higher than that of control cultures which 
reached  a  maximum  of  0.35  mg  l−1.  All  the  transformed  cultures  were  grown  in  hormone-
autotrophic MS medium supplemented with 30 g l−1 sucrose at 25  ◦C under diffuse fluorescent 
light providing 37.5 mmol−2 s−1 light intensity in 12 h photoperiods.
24. Wu-Yang  Huang et.  al.,  (2007)49 investigated  fungal  endophytes  associated  with  a  medicinal 
plant,  Nerium oleander L.(Apocynaceae).  A total  of 42 endophytic fungal strains were isolated 
from the host plant. Total antioxidant capacity, xanthine oxidase inhibitory activity, antimicrobial 
activity,  and total  phenolic  content  (TPC) were evaluated  for  16 representative  fungal  cultures 
grown in improved Czapek’s broth and for the host plant. A significant positive correlation was 
found between antioxidant capacity and TPC in the tested samples. Most of the endophytic fungal 
cultures tested have a wide range of antimicrobial activities, which were not very strong, but much 
better than those of the host plant. The major bioactive constituents of the fungal cultures were 
investigated using LC-ESI-MS and GC-MS, and preliminary identification detected phenolics (e.g. 
phenolic acids and their derivatives, flavonoids) and volatile and aliphatic compounds. This study 
shows that the endophytic fungi isolated from N. Oleander can be a potential antioxidant resource.
25. Osman Goktas et. al., (2007)45 determined the antifungal properties of poisonous plant extracts 
from oleanders (Nerium oleander L.) when used as a wood preservative. The extract was prepared 
from oleanders leaves and flowers in 96% ethyl alcohol. The wood blocks of Turkish oriental beech 
(Fagus orientalis L.) and Scots pine (Pinus sylvestris L.) were impregnated with the extracts. The 
abilities  of  the  extract  to  suppress  attack  by  Postia  placenta  (Fr.)  (brown  rot)  and  Trametes 
versicolor (L: Fr.) Quel. (a white-rot) was investigated. Treated blocks were exposed to P. placenta 
and T. versicolor attacks for 12 weeks by following the soil-block method. While untreated wood 
specimens  have  weight  loss  ranging  between 27.37  and 30.66% for  P.  placenta  and 8.64 and 
24.06% for  T. versicolor, the wood treated with the extracts is of weight loss between 5.54 and 
10.98% for  P. placenta, and between 5.02 and 28.25% for  T. versicolor. The lowest weight loss 
was  found  to  be  for  beech  wood  (5.02%)  impregnated  with  the  extract  of  oleander  at  a 
concentration level of 0.25% against  T. versicolor.  While the highest weight loss was also on the 
beech wood (28.25%) treated with the same extract at the level of 0.50% concentration against T.  
versicolor. In conclusion, the extracts could be used as effective wood preservative.
26. R.N. Kharwar et. al., (2007)51 studied the endophytes of  Azadirachta indica  A. Juss (the neem 
tree) growing in several of its natural habitats in India. A total of 233 isolates of endophytic fungi 
representing 18 fungal taxa were obtained from segments of bark, stem, and leaves of this tree. 
Hyphomycetes  (62.2%)  were  the  most  prevalent  followed  by  the  Coelomycetes  (27.4%)  and 
Mycelia Sterilia (7.7%). Endophytic colonization frequency was also greater in leaves (45.5%) than 
bark (31.5%). The dominant endophytic fungi isolated were  Phomopsis oblonga,  Cladosporium 
cladosporioides, Pestalotiopsis sp., Trichoderma sp, and Aspergillus sp. Genera such as Periconia,  
Stenella, and Drechslera are reported here for the first time as endophytes from this host plant. The 
rich and sizeable collection of endophytic fungi from this specific plant may represent a unique 
source of one or more of the interesting and useful bioactive compounds normally associated with 
A. indica such as the azadirachtins and related tetranortriterpenoids.
27. Nageswara  Rao  et.  al.,  (2007)57 examined  the  effect  of  methanolic  extract  of  Talinum 
portulacifolium (METP) leaves for its anti-hyperglycemic activity against alloxan induced diabetes. 
The  anti-hyperglycemic  effect  of  METP  was  evaluated  in  alloxan  induced  diabetic  rats  by 
monitoring its effect on blood glucose, serum lipid profiles (triglycerides and total cholesterol), 
liver glycogen, malondialdehyde and reduced glutathione (GSH) levels. The rats, pretreated with 
METP (400 mg/kg p.o) improved oral glucose tolerance compare to glucose fed rats. After oral 
administration  of  METP  in  diabetic  rats  for  15  days,  the  blood  glucose,  lipid  profile  and 
malondialdehyde has significantly decreased, while liver glycogen and reduced glutathione were 
increased  significantly.  Histopathological  studies  of  the  pancreas  of  these  animals  showed 
comparable regeneration by METP, which were earlier necrosed by alloxan. Antihyperglycemic 
activity of METP was compared with oral hypoglycemic agent, glibenclamide.
28. José  Alberto  Pereira  et.  al.,  (2008)56 studied  the  total  phenols  content  and  antioxidant  and 
antimicrobial activities in walnut (Juglans regia L.) green husks aqueous extracts of five different 
cultivars (Franquette, Mayette,  Marbot, Mellanaise and Parisienne). The antioxidant capacity of 
aqueous extracts was assessed through reducing power assay, scavenging effects on DPPH (2,2-
diphenyl-1-picrylhydrazyl)  radicals  and  b-carotene  linoleate  model  system.  A  concentration-
dependent antioxidative capacity was verified in reducing power and DPPH assays,  with EC50 
values lower than 1 mg/mL for all the tested extracts. All the extracts inhibited the growth of Gram 
positive bacteria, being Staphylococcus aureus the most susceptible one with MIC of 0.1 mg/mL 
for all the extracts. The results obtained indicate that walnut green husks may become important in 
the  obtainment  of  a  noticeable  source  of  compounds  with  health  protective  potential  and 
antimicrobial activity.
4. AIM AND OBJECTIVE
The significance of natural products in the drug discovery and development processes has been 
reported extensively. The importance of natural products as sources of innovative therapeutic agents 
can  be  illustrated  by the  drugs  used  in  the  control  of  infectious  diseases,  cancer,  lipid  disorders, 
immunomodulation and heart diseases. However, one crucial aspect to be considered for a successful 
natural product-based drug discovery program is the selection of the natural source to be studied. It is 
important to take into account that unexplored and/or underexplored sources of biological diversity are 
often  related  to  novel  chemical  diversity.  Endophytic  fungi  have  been  considered  to  be  untapped 
sources of natural products and should be included in the search for new and innovative biologically 
active compounds.
The cost of cardiac glycosides of Nerium Oleander (oleandrin, oleandrigenin etc.) is very high 
(Rs.600000-1000000/gm).  Average  content  of  oleandrin  is  0.018% weight/wet  weight  of  leaf.  An 
aqueous extract of the plant (AnvirzelTM) is used to treat cancers. The endophytic fungi produce similar 
secondary metabolites or their derivatives as the host plant.
Evaluation of the biological activities of the endophytic fungi from  Nerium Oleander  is the 
main objective of the present study.  The number of metabolites produced by fungal endophytes is 
larger than any other endophytic microorganism class. This may of course be a consequence of the high 
frequency of isolation of fungal endophytes from plant.
5. PLAN OF WORK
1. Collection and identification of host plant
2. Isolation of endophytic fungi
3. Primary screening
• Giant colony technique
• Baljet test
4. Cultivation of selected endophytic fungi on improved Czapek’s broth medium
5. Separation and lyophilization of supernatant
6. Screening for the following biological activities:
• Antifungal activity
• Acute oral toxicity studies
• Cardiotonic activity
• Antidiabetic activity
• Cytotoxic activity
6. MATERIALS AND INSTRUMENTS
TABLE 6.1 MATERIALS
Sr. 
No.
Name of Chemical Supplier
1 Agar HIMEDIA, MUMBAI
2 Alloxan tetrahydrate SD FINE, MUMBAI
3 Ampicillin HIMEDIA, MUMBAI
4 Carboxymethyl cellulose LOBA CHEMICALS, MUMBAI
5 Copper sulphate HIMEDIA, MUMBAI
6 Cycloheximide HIMEDIA, MUMBAI
7 Diazepam RANBAXY, MUMBAI
8 Dipotassium hydrogen phosphate MERCK
9 Dulbecoo’s phosphate buffer saline MP BIOMEDICALS
10 EDTA MP BIOMEDICALS
11 Ethanol LOBA CHEMICALS, MUMBAI
12 Ferrous sulphate HIMEDIA, MUMBAI
13 Fetal Bovine Serum BIOCLOT
14 Gliclazide CADILA, AHMEDABAD
15 Magnesium sulphate NICE CHEMICALS, COCHIN
16 Methanol LOBA CHEMICALS, MUMBAI
17 Orthophosphoric acid  QUALIGENS, MUMBAI
18 Phosphoric acid SD FINE, MUMBAI
19 Picric acid CENTRAL DRUG HOUSE, MUMBAI
20 Potassium chloride MERCK
21 Rat chaw pallets HINDUSTAN LEVER LTD, MUMBAI
22 Sabouraud dextrose agar HIMEDIA, MUMBAI
23 Sodium bicarbonate MP BIOMEDICALS
24 Sodium hydroxide pellets NICE CHEMICALS, COCHIN
25 Sodium hypochlorite NICE CHEMICALS, COCHIN
26 Sodium Nitrate NICE CHEMICALS, COCHIN
27 Sodium-potassium tatarate VIKASH PHARMA, MUMBAI
28 Streptomycin NICHOLAS PIRAMAL, MUMBAI
29 Sucrose SD FINE, MUMBAI
30 Sulfuric acid SD FINE, MUMBAI
31 Trichloro acetic acid MERCK
32 Trypsin INVITROGEN
33 Vanillin HIMEDIA, MUMBAI
34 Yeast extract HIMEDIA, MUMBAI
6.2 INSTRUMENTS
Sr. 
No.
Name Of Instrument Supplier
1 Autoclave New Lab
2 Biosafety cabinet classII Esco
3 CO2 incubator RS Biotech, mini galaxy A
4 Colony counter Neo Lab
5 Cooling centrifuge Remi C24-BL
6 Deep freezer Blue star
7 Double beam UV/VIS Spectrophotometer ELICO, Mumbai
8 Electrocardiogram BIOPAC MP30 system, Germany
9 Electronic Balance Schimadzu, Japan
10 ELISA plate reader Thermo
11 Fluorescence inverted microscope Leica DM IL
12 Glass wares Borosil
13 Glucometer Roche
14 Incubator Genuine
15 Laminar air flow Scientec genuine
16 Micropipettes Eppendorff
17 Refrigerator Godrej
18 RO water system Millipore
19 Rotary flash evaporator Super fit, India ltd.
20 Shaker  Neo Lab
21 Sonicator  PCI, Mumbai
22 Vaccume Filteration unit  Super Fit, India
23 Water Bath Genuine
7. EXPERIMENTAL INVESTIGATIONS
7.1 ISOLATION OF ENDOPHYTIC FUNGI49-52
 Collection of Host Plant
Fresh mature leaves, stems and roots of  Nerium oleander  Linn (Apocynaceae) were collected 
from a healthy plant from the local region of Tamilnadu. The plant was identified at Botanical survey 
of India (BSI) Coimbatore, India. The samples were taken to the laboratory and treated within 3 h.49
 Isolation of endophytic fungi
Samples of leaves, stems and root from Nerium oleander plants were first washed in running 
water. Washing included a sonication step to dislodge any soil and organic matter from the roots. The 
leaves were cut into segments (5 x 5 mm), and stems and roots were cut into pieces (10 mm in length). 
They were surface  sterilized with 75% ethanol for 1 min and 2.5% sodium hypochlorite for 15 min, 
then rinsed in sterile water for three times and cut into 1 cm long segments. Both borders of sterilized 
segments were cut off, and the rest was incubated at 28±1  ◦C on SDA medium supplemented with 
200µg/mL ampicillin and 200µg/mL streptomycin (to inhibit the bacterial growth) until the mycelium 
or colony originating from the newly formed surface of the segments appeared. The mycelium was 
purified in the same condition. Another segment of the same origin without surface sterilization was 
cultured as a negative control to check the presence of contaminated microbes on the segment surface. 
Efficiency of surface sterilization was checked by inoculation the surface imprints of segments and 
pieces.  The purified endophytic fungi were numbered and transferred to fresh SDA slants separately 
and were kept at 4 ◦C after being cultured at 28±1 ◦C for 7 days.50-52
 Cultivation of endophytic fungi
The fresh mycelia (grown on SDA plates at  28±1 ◦C for 3–6 days) of  endophytic fungi with 
different morphology were inoculated into 250-mL flasks containing 100 mL of improved Czapek’s 
broth medium (sucrose, 30 g; NaNO3, 3 g; K2HPO4, 1 g; yeast extract, 1 g; KCl, 0.5 g; MgSO4.7H2O, 
0.5 g; FeSO4, 0.01 g; H2O, 1000 mL; autoclaved at 121°C for 20 min), followed by incubation in a 
shaking incubator at 140 rpm for 15 days at 28°C. The culture broth of each endophyte was centrifuged 
at 10000 rpm for 10 min and filtered using a filter with a 0.44µm nylon membrane under vacuum at 
~23  °C to  remove  mycelium.  The  filtrate  volume  was  reduced  using  rotary  flash  evaporator. 
Concentrated filtrate was then stored at 4 °C until use within 24 hours.49
7.2 PRIMARY SCREENING
 Giant colony technique53
• Principle
The fungal cultures are inoculated onto the central areas of petri plates containing a nutritious 
agar medium, or they are streaked in a narrow band across the centers of the plates. The plates are then 
incubated  until  growth  and,  possibly,  sporulations  have occurred.  Strains  of  microorganisms to  be 
tested for possible sensitivity to the antibiotics (the test organism) are then streaked from the edges of 
the plates up to but not touching the fungal growth. The plates are further incubated to allow growth of 
the test  organism, and the distance over which the growth of test  organism has been inhibited by 
antibiotic in the vicinity of the fungi is then measured in millimeters. Obviously, whose growth has 
been inhibited for a considerable distance from the fungi colony, are more sensitive to the antibiotic 
than those test microorganisms that can grow close to the fungi colony. Only those fungi that have 
produced antibiotics with interesting microbial inhibition spectra are retained for further testing.
• Procedure
Sauboard dextrose agar medium was prepared, sterilized and cooled. The media was poured 
into Petri dishes and allowed to solidify. Isolated fungi (F1 to F8) were streaked on media at straight 
line and incubated at 28±1°C for 4 days. The test fungi were then streaked at an angle of 90° and 
incubated at  28±1°C for 24 hrs.  The length of inhibition was observed if  any.  The fungi showing 
antifungal activity were further confirmed by agar diffusion method.
 Baljet reaction 54-55
• Principle
Cardenolides  give  a  yellow  orange  color  with  alkaline  picrate  solution.  The  yellow  color 
reaches  its  intensity  maximum  10  minutes  after  the  addition  of  the  NaOH  solution  and  remains 
unchanged for about 15 min.
• Procedure
A portion of the filtrate was dissolved in methanol (1:1). To 2.5 mL of this solution 2.5 mL 
aqueous picric acid (1.3 % w/v) was added. Entire content was diluted with 0.6 mL distilled water and 
made alkaline with 0.6 mL NaOH. The absorbance of the resulting solution was measured at 490 nm 
for 15 minute at 1 minute time interval. Fungi showing best color reaction in baljet test were cultivated 
in large scale by similar incubation conditions. The supernatant was collected after centrifugation and 
lyophilized. The lyophilized product was further studied for biological activities.
7.3 BIOLOGICAL SCREENING
 In vitro antifungal study56
The  screening  of  antifungal  activity  for  the  determination  of  the  minimal  inhibitory 
concentration (MIC) was achieved by an adaptation of the agar streak dilution method based on radial 
diffusion. Suspensions of the microorganism were prepared to contain approximately 108 cfu/mL, and 
the plates containing agar medium were inoculated (100 µL; spread on the surface). The sample (50 µL 
F3 and F4 metabolites) of varying concentrations were placed in a hole (3 mm depth, 6 mm diameter) 
made in the nutritious agar and allowed to diffuse in the media for 2 h (at  4°C). Under the same 
conditions, different solutions of cycloheximide were used as standards. The MIC was considered to be 
the  lowest  concentration  of  the  tested  sample  able  to  inhibit  the  growth of  fungi  after  48  h.  The 
diameters of the inhibition zones corresponding to the MICs were measured using a ruler, with an 
accuracy of 0.5 mm. Each inhibition zone diameter was measured three times (three different plates) 
and the average was considered. A control using only inoculation was also carried out.
 Animals57
All the experiments were carried out using male Swiss Albino mice (25-30g) and Wistar Rats 
(150-200 gm) procured from the animal house, IRT Perundurai Medical College,  Erode, India.  On 
arrival the animals were placed at random and allocated to treatment groups in polypropylene cages 
with paddy husk as bedding. Animals were housed at a temp of 24±2 ◦C and 30-70% relative humidity. 
A 12:12 h light: dark cycle was followed. All animals were allowed to free access to water and fed with 
standard commercial rat chaw pallets. All the experimental procedures and protocols used in this study 
were  reviewed  by  the  institutional  animal  ethics  committee  (Regd.  no:  688/02/C-CPCSEA  date: 
21-02-2002) and were in accordance with the guidelines of the CPCSEA.
 Acute oral toxicity studies57
An acute oral toxicity study was performed according to OECD-423 guidelines (acute toxic 
class method). Swiss albino mice (25-30g) (n=3) of either sex selected by random sampling technique 
are employed in this study. The animals were fasted for 4 h with free access to water only. F3 and F4 
were administered orally at  a dose of 5mg/kg (suspended in 0.5% CMC) initially and mortality is 
observed for 3 days.  If  mortality is  observed in  2/3 or 3/3 animals,  then the dose administered is 
considered as toxic dose. However, if the mortality is observed in only one animal out of 3 animals 
then the same dose is  repeated again to confirm the toxic  effect.  If  mortality is  not  observed,  the 
procedure is repeated with higher doses such as 50, 300 and 2000mg/kg.
 In vivo cardiotonic activity4, 58
Male Wistar rats  were divided in three groups (n=2).  Group 1 served as control and orally 
received 0.5% CMC solution only. Group 2 animals were orally fed with 1000mg/kg of F3 metabolites 
suspended  in  0.5%  CMC  solution  and  Group  3  animals  were  orally  fed  with  1000mg/kg  of  F4 
metabolites suspended in 0.5% CMC.
The animals were anaesthetized with intra muscular injection of diazepam (1mg/kg) one hour 
after  giving dose.  ECG was recorded using electrocardiogram. The red and black electrodes  were 
applied on right and left hind arm near femoral vein respectively. The white electrode was applied on 
the left  forearm near thoracic cavity.  All  leads were established by surface electrodes to minimize 
injury to the animal. The output signals of these systems were recorded at 50-150 Hz.
 In Vivo Antidiabetic Study57, 59-60
• Induction of diabetes
Male Wistar rats weighing 150–200 g were used for this study. For the induction of diabetes, 
rats were kept on fasting for 24 hours prior to alloxan injection. On the day of administration, alloxan 
tetrahydrate was freshly dissolved in 0.01 M (pH 4.5) citrate buffer and subcutaneous injection was 
given at the dosage of 250 mg/kg. Blood glucose concentration was checked by the Glucometer after 1 
week  of  alloxan  injection.  The  animals  with  glucose  concentration  exceeding  250  mg/dl  were 
considered diabetic.59
• Experimental Design
All the rats were divided into 5 groups:
Group 1 Control animals received citrate buffer injection only
Group 2 Diabetic animals received alloxan injection
Group 3 Diabetic animals orally fed with 8 mg/kg of gliclazide suspended in 0.5% 
carboxymethyl cellulose (CMC) solution in two divided doses orally for 
15 days
Group 4 Diabetic animals orally fed with 500mg/kg of F3 metabolites suspended in 
0.5% (CMC) solution in two divided doses for 15 days
Group 5 Diabetic animals orally fed with 1000mg/kg of F3 metabolites suspended 
in 0.5% (CMC) solution in two divided doses for 15 days
All groups except group 1 received their respective solutions through cannula. Group 2 received 
vehicle (0.5% CMC solution) only.60
• Body weight
The body weights of the animals were measured before and after the study period.60
• Biochemical analysis
a) Collection of serum
The animals were fasted overnight and the blood samples were withdrawn from retro-orbital 
plexus under light ether anesthesia without any anticoagulant and allowed to clot for 10 minutes at 
room temperature. It was centrifuged at 2500 rpm for 20 minutes. The serum obtained was kept at 4ºC 
until used.57
b) Estimation of Fasting Glucose
In vitro quantitative determination of the activity of glucose in serum was done using enzymatic 
kit (Beacon Diagnostics Pvt. Limited.).57
→ Principle:
Enzymatic colorimetric determination of glucose according to the following reactions:
→ Procedure
Pipette in the tubes labeled as follows;
Blank Standard Sample
Working Reagent 2 ml 2 ml 2 ml
Distilled Water 10 µl - -
Standard - 10 µl -
Serum Sample - - 10 µl
Mix and read the optical density (OD) at 356 nm after 10 minutes incubation. The final color is 
stable for at least 1 hour.
→ Calculations
Fasting Glucose (mg/dl) = Abs. of sample/ Abs. of Std. X 100
c) Estimation of total protein (Biuret method)
In vitro quantitative measurement of total protein concentration in serum was done by using kit 
(Span diagnostics (India) Pvt. Ltd.).
→ Principle
Peptide bonds in protein react with cupric ion in alkaline solutions to form a colored chelate, the 
absorbance of which is measured at 578 nm. The Biuret reagent contains sodium-potassium tartarate to 
complex cupric ions and maintains their solubility at alkaline pH. Absorbance data is proportional to 
protein concentration.
Biuret reagent: Copper sulphate, Sodium hydroxide, Sodium-potassium tatarate, Surfactant.
Protein Standard: 6.5 mg/dl
→ Procedure
Pipette in the tubes labeled as follows;
Blank Standard Test
Serum - - 30 µl
Total Protein standard - 30 µl -
Biuret Reagent 3.0 ml 3.0 ml 3.0 ml
Mix well and incubate at 37ºC or at room temperature for 5 minutes. Read the absorbance at 
578 nm against reagent blank.
→ Calculations:
Total Protein = Abs. of Test/ Abs. of Std. X 6.557
d) Estimation of total lipids (Sulphophosphovanillin method)
→ Principle
Lipids react with vanillin in the presence of sulfuric and phosphoric acid to form a pink colored 
complex.
→ Reagents
1. Total lipid standard: 1000 mg/dL
It is prepared by dissolving 1.0 gm of olive oil in chloroform.
2. Color reagent (Phosphovanillin) is prepared by mixing
a. 0.61 gm/dl vanillin      : 350 ml
b. Orthophosphoric acid  : 600 ml
c. Distilled water             : 50 ml 
3. Concentrated sulfuric acid (AR)
→ Procedure
Pipette in the tubes labeled as follows;
Test Standard
Solution 1 - 0.05 ml
Serum 0.05 ml -
Reagent 3 2.0 ml 2.0 ml
Mixed thoroughly and plugged with cotton wool. Then it was kept in a boiling water bath for 10 
minutes. Then cooled in cold water bath and again pipetted into dry test tubes as follows:
Test Std. Blank
From above solution 0.10 ml 0.10 ml -
Reagent 3 - - 0.10 ml
Coloring reagent 2.5 ml 2.5 ml 2.5 ml
Mixed thoroughly and kept at room temperature (25ºC ± 5ºC) for 15 minutes. Read absorbance 
of test and standard against blank in a dry cuvette at 546 nm.57
→ Calculations 
Serum Total Lipid (mg/dl) =   O.D. of Test/ O.D. of Std.    X 100
• Statistical analysis
All the values of body weight and biochemical estimations were expressed as mean ± standard error 
of  mean  (S.E.M.)  and  analyzed  by  one-way  ANOVA  followed  by  Turkey-Kramer  Multiple 
Comparison Test. Differences between groups were considered significant at P < 0.01 levels.
In Vitro Cytotoxic Study (Sulphorodamine B, SRB assay)61
• Principle
SRB  is  a  bright  pink  aminoxanthine  dye  with  two  sulfonic  groups.  Under  mild  acidic 
conditions,  SRB  binds  to  basic  amino acid  residues  in  TCA (Trichloro  acetic  acid)  fixed  cells  to 
provide a sensitive index of cellular protein content that is linear over a cell density range of visible at 
least two order of magnitude.
• Media
→ DMEM (Dulbecoo’s Modified Eagels medium, high glucose)
→ FBS (Fetal Bovine Serum)
• Glass wares and plastic wares
96-well microtiter plate, Tissue culture flasks, Falcon tubes, Reagent bottles
• Cancer cell lines
hep 2, mcf 7, hela and hek (National Centre For Cell Science, Pune)
• Procedure
1. The monolayer cell culture was trypsinized and the cell count was adjusted to 0.5-1.0 x 105 
cells/ml using medium containing 10% new born sheep serum.
2. To each well of the 96 well microtitre plate, 0.1ml of the diluted cell suspension (approximately 
10,000 cells) was added.
3. After 24 hours, when a partial monolayer was formed, 100µl of different compound (F3 and F4 
metabolites) concentrations were added to the cells in microtitre plates. The plates were then 
incubated at 37oC for 72 hours in 5% CO2 incubator and microscopic examination was carried 
out and observations recorded every 24 hours.
4. After 72 hours, 25µl of 50% trichloroacetic acid was added to the wells gently such that it 
forms a thin layer over the test compounds to form a over all concentrations 10%.
5. The plates were incubated at 4oC for one hour.
6. The plates were flicked and washed five times with tap water to remove traces of medium, 
sample and serum, and were then air-dried.
7. The air-dried plates were stained with 100μl SRB and kept for 30 minutes at room temperature. 
The unbound dye was removed by rapidly washing four times with 1% acetic acid. The plates 
were then air-dried.
8. 100µl of 10mM Tris base was then added to the wells to solubilize the dye. The plates were 
shaken vigorously for 5 minutes.
9. The absorbance was measured using ELISA plate reader at a wavelength of 620 and 540nm.
10. The percentage growth inhibition was calculated using following formula, 
%cell inhibition= 100-{(At-Ab)/ (Ac-Ab)} x100
Where, At= Absorbance value of test compound
Ab= Absorbance value of blank
Ac=Absorbance value of control
8. RESULTS AND DISCUSSION
8.1 ISOLATION OF ENDOPHYTIC FUNGI
Total 8 endophytic fungi were isolated from Nerium oleander and given code as follows:
Stem: F5
Leaf: F2 and F6
Root: F1, F3, F4, F7 and F8
Figure 8.1: F1
Figure 8.2: F2
Figure 8.3: F3
Figure 8.4: F4
Figure 8.5: F5
Figure 8.6: F6
Figure 8.7: F7
Figure 8.8: F8
8.2 PRIMARY SCREENING
 Giant colony technique
The endophytic fungi F3 and F4 showed antifungal activity against some test fungi. The results 
are shown in the table 8.1.
Table 8.1 Inhibition of growth of test fungi by endophytic fungi
F1 F2 F3 F4 F5 F6 F7 F8
Arthrobotrys oligospora (NCIM 1246) N N Y Y N N N N
Aspergillus niger (NCIM 1207) N N Y Y N N N N
Auricularia polytricha (NCIM 1303) N N N N N N N N
Candida albicans (NCIM 3484) N N Y Y N N N N
Chaetomella raphigera (NCIM 1231) N N Y Y N N N N
Monilinia fruticola (NCIM 1011) N N N N N N N N
Sacchromyces cerevisae (ATCC 204508) N N Y Y N N N N
N→no inhibition; Y→inhibition of growth of test fungi
Endophytic fungi F3 and F4 were thus cultivated on large scale for in vitro antifungal activity.
 Baljet reaction
The absorbances of the reaction product of Baljet test at 490 nm for 15 minute at 1 minute time 
interval are as follows:
Figure 8.9: Baljet reaction
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The figure shows that F3 and F4 metabolites showed best color reaction in baljet test. They 
were thus cultivated on large scale for biological screening.
8.3 BIOLOGICAL SCREENING
Endophytic fungi F3 and F4 were cultivated in large scale for biological screening. The medium 
and incubation conditions were described in the procedure. After incubation period the mycelium was 
separated by centrifugation. Resulting supernatant was freeze dried and the freeze dried product was 
used for the study.
Figure: 8.10 Freeze Dried Powder of Endophytic Fungi supernatant
F3 F4
 In vitro antifungal study
The endophytic fungi F3 and F4 were screened for their antifungal properties against A. oligospora, 
A. niger, A. polytricha, C. albicans, C. raphigera, M. fruticola and S. cerevisae. The minimal inhibitory 
concentration (MIC) values for the tested fungi were determined as an evaluation of the antimicrobial 
activity of the tested freeze dried supernatant of the endophytic fungal culture. The results are shown in 
table 8.2. The response for each microorganism tested was different. The endophytic fungi revealed 
antifungal  activity  showing  different  selectivity  and  MICs  for  each  test  fungi.  The  pure  active 
compound cycloheximide presented lower MICs than the endophytic fungi.
Figure 8.11: Antifungal activity of F3 metabolites against Arthrobotrys oligospora 
Table 8.2: Antifungal activity of metabolites of F3 and F4, and Cycloheximide
Test Organism MIC (mg/ml)*F3 F4 Cycloheximide
Arthrobotrys oligospora 13 13.5 0.50
Aspergillus niger 13.5 12.5 1.00
Candida albicans 15 14.5 0.50
Chaetomella raphigera 14 13 0.50
Sacchromyces cerevisae 12.5 12 0.75
*- calculated as freeze dried powder of the fungal culture
 Acute oral toxicity studies
F3 and F4 metabolites did not cause any mortality up to 2000 mg/kg and were considered as 
safe. No lethality or any toxic reactions were found up to the end of the study period.
 In vivo cardiotonic activity:
There was no significant change in the ECG pattern of F3 metabolite administered group and a 
slight prolongation of PR interval (delayed atrioventricular conduction) in F4 metabolite administered 
group. It confirms a mild cardiotonic activity of F4 metabolite on rat heart.
Figure 8.12: ECG of Group 1 (control group)
Figure 8.13: ECG of Group 2 (F3 metabolite administered group)
Figure 8.14 
ECG of 
Group 3 (F4 
metabolite 
administered group)
 In Vivo Antidiabetic Study
Figure 8.15: Oral Drug Administration to Rat
• Body weight change
Treatment with F3 reversed the weight loss in diabetic rats. It is given in table.
Table 8.3: Average body weight (g) of experimental groups (n=6)
Initial Final
Group 1 187.00 ± 4.06 190.33 ± 4.27
Group 2 182.17 ± 2.60 171.33 ± 2.66
Group 3 183.67 ± 2.49 191.33 ± 2.80
Group 4 184.67 ± 3.06 197.83 ± 3.43
Group 5 183.17 ± 2.89 190.67 ± 3.21
• Biochemical analysis
The results  of the present investigation are presented in Table 8.4-8.7. In all  groups before 
alloxan administration, the basal levels of blood glucose of the rats were not significantly different. 
However, 7 days after alloxan administration, blood glucose levels were significantly higher in the 
experimental  rats  selected for the study.  Table  presents  the changes  in body weight,  fasting blood 
glucose, total lipids and total proteins in normal and experimental diabetic rats. The body weights in the 
F3 metabolite-treated  and  gliclazide-treated  groups increased  significantly (P<0.001)  at  the  end of 
week 2 when compared with the diabetic control group. A significant antihyperglycemic effect was 
observed in the F3-treated and gliclazide-treated groups (P<0.001). The serum total protein values were 
significantly decreased in gliclazide-treated group (P<0.01) while there is no significant decrease in F3 
treated group as compared with the diabetic control group. The values of serum total lipids shows a 
significant decrease in the F3-treated and gliclazide-treated groups (P<0.001).
Table 8.4: Serum fasting glucose of experimental groups*
Absorbance of test Absorbance of standard Fasting glucose (mg/dl)
Group 1 0.278 0.397 70.025
Group 2 0.966 0.397 243.325
Group 3 0.347 0.397 87.406
Group 4 0.661 0.397 166.499
Group 5 0.382 0.397 96.222
*→Values are represented as mean (n=6)
Figure 8.16 Serum fasting glucose of experimental groups**
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**→Values are represented as mean ± standard error of mean (n=6)
Table 8.5: Serum total protein of experimental groups*
Absorbance of test Absorbance of standard Total protein (gm/dl)
Group 1 0.532 0.461 7.501
Group 2 0.681 0.461 9.602
Group 3 0.494 0.461 6.965
Group 4 0.598 0.461 8.432
Group 5 0.543 0.461 7.656
*→Values are represented as mean (n=6)
Figure 8.17 Serum total protein of experimental groups**
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**→Values are represented as mean ± standard error of mean
Table 8.6: Serum total lipids of experimental groups*
 Absorbance of test Absorbance of standard Total lipids (mg/dl)
Group 1 0.074 0.032 231.563
Group 2 0.823 0.032 2571.875
Group 3 0.079 0.032 245.313
Group 4 0.553 0.032 1728.125
Group 5 0.326 0.032 1018.750
*→Values are represented as mean (n=6)
Figure 8.18: Serum total lipids of experimental groups**
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**→Values are represented as mean ± standard error of mean
In Vitro Cytotoxic Study (Sulphorodamine B, SRB assay)
F3 and F4 metabolites were screened for cytotoxic activity using SRB assay. F3 metabolites 
showed cytotoxic effect on mcf 7 while it does not possess significant cytotoxicity against hep 2, hela 
and hek cell lines. F4 metabolites showed significant cytotoxicity against mcf 7 and hela cell lines 
while it has less significant action on hep 2 and hek cell lines. The results of SRB assay are shown in 
the tables (8.8-8.15) and figures (8.19-8.26):
Table 8.8: Cytotoxic Effect of F3 metabolites on HEP 2
 Absorbance % cell inhibition
Concentration of F3 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.118 0.199 - -
control 0.047 0.067 - -
0.0196 0.102 0.156 77.46 67.42
0.0391 0.075 0.113 39.44 34.85
0.078 0.062 0.089 21.13 16.67
0.156 0.061 0.079 19.72 9.09
0.312 0.053 0.07 8.45 2.27
0.625 0.074 0.093 38.03 19.70
1.25 0.07 0.086 32.39 14.39
2.5 0.07 0.085 32.39 13.64
5 0.057 0.067 14.08 0.00
10 0.082 0.107 49.30 30.30
Figure 8.19: Cytotoxic Effect of F3 metabolites on HEP 2
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
0.
02
0.
04
0.
08
0.
16
0.
31
0.
63
1.
25 2.
5 5 10
Concentration of F3 (mg/ml)
%
 c
el
l i
nh
ib
iti
on
690 nm
540 nm
Table 8.9: Cytotoxic Effect of F4 metabolites on HEP 2
 Absorbance % cell inhibition
Concentration of F4 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.124 0.226 - -
control 0.056 0.083 - -
0.0196 0.103 0.168 69.12 59.44
0.0391 0.084 0.151 41.18 47.55
0.078 0.22 0.218 241.18 94.41
0.156 0.093 0.152 54.41 48.25
0.312 0.065 0.097 13.24 9.79
0.625 0.094 0.15 55.88 46.85
1.25 0.063 0.084 10.29 0.70
2.5 0.081 0.114 36.76 21.68
5 0.074 0.087 26.47 2.80
10 0.066 0.079 14.71 -2.80
Figure 8.20: Cytotoxic Effect of F4 metabolites on HEP 2
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Table 8.10: Cytotoxic Effect of F3 metabolites on MCF 7
 Absorbance % cell inhibition
Concentration of F3 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.045 0.051 - -
control 0.077 0.123 - -
0.0196 0.158 0.206 -253.13 -115.28
0.0391 0.142 0.188 -203.13 -90.28
0.078 0.129 0.174 -162.50 -70.83
0.156 0.116 0.154 -121.88 -43.06
0.312 0.108 0.139 -96.88 -22.22
0.625 0.091 0.126 -43.75 -4.17
1.25 0.077 0.111 0.00 16.67
2.5 0.062 0.097 46.88 36.11
5 0.047 0.082 93.75 56.94
10 0.026 0.068 159.38 76.39
Figure 8.21: Cytotoxic Effect of F3 metabolites on MCF7 
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Table 8.11: Cytotoxic Effect of F4 metabolites on MCF 7
 Absorbance % cell inhibition
Concentration of F4 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.049 0.07 - -
control 0.186 0.245 - - 
0.0196 0.124 0.231 45.26 8.00
0.0391 0.098 0.213 64.23 18.29
0.078 0.086 0.196 72.99 28.00
0.156 0.069 0.175 85.40 40.00
0.312 0.055 0.152 95.62 53.14
0.625 0.044 0.125 103.65 68.57
1.25 0.031 0.108 113.14 78.29
2.5 0.025 0.075 117.52 97.14
5 0.011 0.055 127.74 108.57
10 0.001 0.035 135.04 120.00
Figure 8.22: Cytotoxic Effect of F4 metabolites on MCF 7
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Table 8.12: Cytotoxic Effect of F3 metabolites on HELA
 Absorbance % cell inhibition
Concentration of F3 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.072 0.112  - -
control 0.12 0.201 - - 
0.0196 0.19 0.308 -145.83 -120.22
0.0391 0.122 0.206 -4.17 -5.62
0.078 0.232 0.298 -233.33 -108.99
0.156 0.159 0.234 -81.25 -37.08
0.312 0.109 0.187 22.92 15.73
0.625 0.086 0.111 70.83 101.12
1.25 0.059 0.078 127.08 138.20
2.5 0.103 0.151 35.42 56.18
5 0.057 0.07 131.25 147.19
10 0.071 0.086 102.08 129.21
Figure 8.23: Cytotoxic Effect of F3 metabolites on HELA
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Table 8.13: Cytotoxic Effect of F4 metabolites on HELA
 Absorbance % cell inhibition
Concentration of F4 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.058 0.061 - - 
control 0.227 0.263 - -
0.0196 0.154 0.242 43.20 10.40
0.0391 0.141 0.221 50.89 20.79
0.078 0.129 0.171 57.99 45.54
0.156 0.112 0.164 68.05 49.01
0.312 0.098 0.144 76.33 58.91
0.625 0.089 0.141 81.66 60.40
1.25 0.074 0.099 90.53 81.19
2.5 0.061 0.099 98.22 81.19
5 0.048 0.071 105.92 95.05
10 0.035 0.066 113.61 97.52
Figure 8.24: Cytotoxic Effect of F4 metabolites on HELA
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Table 8.14: Cytotoxic Effect of F3 metabolites on HEK
 Absorbance % cell inhibition
Concentration of F3 (mg/ml) 690 nm 540 nm 690 nm 540 nm
blank 0.076 0.12 - - 
control 0.287 0.804 - -
0.0196 0.174 0.261 53.55 79.39
0.0391 0.11 0.192 83.89 89.47
0.078 0.239 0.374 22.75 62.87
0.156 0.069 0.112 103.32 101.17
0.312 0.186 0.238 47.87 82.75
0.625 0.011 0.124 130.81 99.42
1.25 0.065 0.1 105.21 102.92
2.5 0.052 0.071 111.37 107.16
5 0.056 0.067 109.48 107.75
10 0.068 0.098 103.79 103.22
Figure 8.25: Cytotoxic Effect of F3 metabolites on HEK
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Table 8.15: Cytotoxic Effect of F4 metabolites on HEK
 Absorbance % cell inhibition
Concentration of F4 (mg/ml) 690 nm 540 nm 690 nm 540 nm
Blank 0.08 0.105 - - 
Control 0.244 0.371 - -
0.0196 0.221 0.37 14.02 0.38
0.0391 0.297 0.416 -32.32 -16.92
0.078 0.39 0.404 -89.02 -12.41
0.156 0.198 0.296 28.05 28.20
0.312 0.068 0.116 107.32 95.86
0.625 0.089 0.132 94.51 89.85
1.25 0.059 0.093 112.80 104.51
2.5 0.078 0.115 101.22 96.24
5 0.054 0.07 115.85 113.16
10 0.075 0.131 103.05 90.23
Figure 8.26: Cytotoxic Effect of F4 metabolites on HEK
-100.00
-50.00
0.00
50.00
100.00
150.00
0.
02
0.
04
0.
08
0.
16
0.
31
0.
63
1.
25 2.
5 5 10
Concentration of F4 (mg/ml)
%
 c
el
l i
nh
ib
iti
on
690 nm
540 nm
9. SUMMARY
Total 8 (one from stem, two from leaf and five from root) endophytic fungi were isolated from 
Nerium oleander. They were screened for antifungal, cardiotonic, antidiabetic and cytotoxic activity.
The fungi were cultivated using improved Czapek’s broth medium. Two fungi (F3 and F4) were 
found to produce antifungal metabolites and inhibited the growth of  Arthrobotrys oligospora (NCIM 
1246),  Aspergillus  niger  (NCIM  1207), Candida  albicans  (NCIM  3484),  Chaetomella  raphigera 
(NCIM 1231), and Sacchromyces cerevisae (ATCC 204508) whereas it showed poor activity against 
Auricularia polytricha (NCIM 1303) and Monilinia fruticola (NCIM 1011).
An  acute  oral  toxicity  study  was  performed  to  determine  the  dose  for  cardiotonic  and 
antidiabetic screening. Signs of toxicity were not observed up to 2000mg/kg of body weight.
F3 was not having any significant change in ECG pattern while F4 prolonged the PR interval in 
the ECG, indicating its mild cardiotonic activity on rat. 
There was a significant recovery of fasting glucose, total lipids and body weights in diabetic 
models (alloxan induced)of rats treated with F3, while it does not showed significant change in serum 
protein level. P values were less than 0.001 in case of body weight, fasting and total lipids, while it was 
not significant for total proteins. The effect was dose dependant.
F3 possessed cytotoxic effect on mcf 7 while it was not having significant cytotoxicity against 
hep 2, hela and hek cell lines. F4 showed significant cytotoxicity against mcf 7 and hela cell lines while 
it showed less significant action on hep 2 and hek cell lines.
10. CONCLUSION
Endophytic  fungi  were  isolated  from  Nerium  Oleander Linn  (Apocynaceae).  They  have 
produced metabolites with antifungal, cardiotonic, antidiabetic and cytotoxic activity without causing 
any toxic effect. AnvirzelTM is an aqueous extract of the plant Nerium oleander which has been utilized 
to treat patients with advanced malignancies. Present study has shown that endophytic fungi have a 
potential to replace the use of host plant therapeutically.
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